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A B S T R A C T
Background
Perioperative fluid strategies influence clinical outcomes following major surgery. Many intravenous fluid preparations are based on
simple solutions, such as normal saline, that feature an electrolyte composition that differs from that of physiological plasma. Buffered
fluids have a theoretical advantage of containing a substrate that acts to maintain the body’s acid-base status - typically a bicarbonate
or a bicarbonate precursor such as maleate, gluconate, lactate, or acetate. Buffered fluids also provide additional electrolytes, including
potassium, magnesium, and calcium, more closely matching the electrolyte balance of plasma. The putative benefits of buffered fluids
have been compared with those of non-buffered fluids in the context of clinical studies conducted during the perioperative period.
This review was published in 2012, and was updated in 2017.
Objectives
To review effects of perioperative intravenous administration of buffered versus non-buffered fluids for plasma volume expansion or
maintenance, or both, on clinical outcomes in adults undergoing all types of surgery.
Search methods
We electronically searched the Clinicaltrials.gov major trials registry, the Cochrane Central Register of Controlled Trials (CENTRAL;
2016, Issue 6) in the Cochrane Library, MEDLINE (1966 to June 2016), Embase (1980 to June 2016), and the Cumulative Index
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to Nursing and Allied Health Literature (CINAHL; 1982 to June 2016). We handsearched conference abstracts and, when possible,
contacted leaders in the field. We reran the search in May 2017. We added one potential new study of interest to the list of ‘Studies
awaiting classification’ and will incorporate this trial into formal review findings when we prepare the review update.
Selection criteria
Only randomized controlled trials that compared buffered versus non-buffered intravenous fluids for surgical patients were eligible for
inclusion. We excluded other forms of comparison such as crystalloids versus colloids and colloids versus different colloids.
Data collection and analysis
Two review authors screened references for eligibility, extracted data, and assessed risks of bias. We resolved disagreements by discus-
sion and consensus, in collaboration with a third review author. We contacted trial authors to request additional information when
appropriate. We presented pooled estimates for dichotomous outcomes as odds ratios (ORs) and for continuous outcomes as mean
differences (MDs), with 95% confidence intervals (CIs). We analysed data via Review Manager 5.3 using fixed-effect models, and when
heterogeneity was high (I² > 40%), we used random-effects models.
Main results
This review includes, in total, 19 publications of 18 randomized controlled trials with a total of 1096 participants. We incorporated
five of those 19 studies (330 participants) after the June 2016 update. Outcome measures in the included studies were thematically
similar, covering perioperative electrolyte status, renal function, and acid-base status; however, we found significant clinical and sta-
tistical heterogeneity among the included studies. We identified variable protocols for fluid administration and total volumes of fluid
administered to patients intraoperatively. Trial authors variably reported outcome data at disparate time points and with heterogeneous
patient groups. Consequently, many outcome measures are reported in small group sizes, reducing overall confidence in effect size,
despite relatively low inherent bias in the included studies. Several studies reported orphan outcome measures. We did not include in
the results of this review one large, ongoing study of saline versus Ringer’s solution.
We found insufficient evidence on effects of fluid therapies on mortality and postoperative organ dysfunction (defined as renal
insufficiency leading to renal replacement therapy); confidence intervals were wide and included both clinically relevant benefit and
harm: mortality (Peto OR 1.85, 95% CI 0.37 to 9.33; I² = 0%; 3 trials, 6 deaths, 276 participants; low-quality evidence); renal
insufficiency (OR 0.82, 95% CI 0.34 to 1.98; I² = 0%; 4 trials, 22 events, 276 participants; low-quality evidence).
We noted several metabolic differences, including a difference in postoperative pH measured at end of surgery of 0.05 units - lower in
the non-buffered fluid group (12 studies with a total of 720 participants; 95% CI 0.04 to 0.07; I² = 61%). However, this difference
was not maintained on postoperative day one. We rated the quality of evidence for this outcome as moderate. We observed a higher
postoperative serum chloride level immediately after operation, with use of non-buffered fluids reported in 10 studies with a total of
530 participants (MD 6.77 mmol/L, 95% CI 3.38 to 10.17), and this difference persisted until day one postoperatively (five studies
with a total of 258 participants; MD 8.48 mmol/L, 95% CI 1.08 to 15.88). We rated the quality of evidence for this outcome as
moderate.
Authors’ conclusions
Current evidence is insufficient to show effects of perioperative administration of buffered versus non-buffered crystalloid fluids on
mortality and organ system function in adult patients following surgery. Benefits of buffered fluid were measurable in biochemical
terms, particularly a significant reduction in postoperative hyperchloraemia and metabolic acidosis. Small effect sizes for biochemical
outcomes and lack of correlated clinical follow-up data mean that robust conclusions on major morbidity and mortality associated
with buffered versus non-buffered perioperative fluid choices are still lacking. Larger studies are needed to assess these relevant clinical
outcomes.
P L A I N L A N G U A G E S U M M A R Y
Buffered versus non-buffered fluids given to adults during surgery
Review question
To review evidence from randomized controlled trials on safety and effects of administration of buffered versus non-buffered fluids into
the veins of adult patients undergoing surgery.
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Background
During surgery, adults are given fluids into their veins to prevent or treat excessive loss of body water and salts (dehydration) and to
compensate for loss of blood. Some fluids consist of a simple salt solution in the same salt concentration as cells and blood, such as
isotonic saline; others are buffered solutions that resist changes in pH when small quantities of an acid or a base are added to them.
Buffered fluids include additional electrolytes, including potassium, magnesium, and calcium, so they are matched more closely to fluid
in the blood.
Study characteristics
We searched the literature up to June 2016 and found 19 studies, with a total of 1096 adults randomly assigned to receive buffered or
non-buffered fluids. Some included trials involved minor surgery in otherwise fit and healthy patients. Other trials analysed outcomes
after major surgery in high-risk patients, and five trials included patients undergoing renal transplant surgery. We reran the search in
May 2017 and decided that we will deal with one new study of interest when we update the review.
Key results
Overall results show that the number of deaths was low and provide no evidence that choice of fluids - buffered or non-buffered -
influenced the number of deaths that occurred around the time of surgery in the three trials that looked at this outcome (involving 267
participants). We found no differences between groups in the numbers of participants whose kidney function was adversely affected.
Analysis of clinical outcomes suggests that buffered fluids are an equally safe and effective alternative to non-buffered fluids for adult
patients undergoing surgery. The pH of the blood after surgery was reduced among patients receiving saline (pH 7.32 vs 7.38),
suggesting that buffered fluids are associated with less metabolic acidosis. The saline group had higher serum chloride and sodium levels
than the buffered fluid group. This might be expected, as members of the saline group were receiving saline and no other electrolytes.
Higher serum chloride is a cause of metabolic acidosis.
Quality of the evidence
We assessed the quality of evidence as generally moderate, although quality of evidence showing effects of fluid choice on kidney
function was low because of the presence of other factors that could affect kidney function in these participants. Evidence shows wide
variation in the types of surgery performed and in drivers for and volumes of fluid administered across trials. Reported outcomes varied
a great deal between included trials, and some results were expressed in ways that did not allow their inclusion in our findings.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Buf fered versus non-buf fered crystalloid intravenous f luid for adults undergoing any form of surgery
Patient or population: adults receiving intravenous f luids whilst undergoing any form of surgery
Setting: elect ive, major surgery in hospitals in Europe, USA, Asia, and the Middle East
Intervention: buf fered crystalloid intravenous f luid
Comparison: non-buf fered crystalloid intravenous f luid
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with non-buffered
fluid
Risk with buffered fluid
Mortality (in-hospital
death and 30-day mor-
tality)
Study populat ion OR 1.85
(0.37 to 9.33)
267
(3 RCTs)
⊕⊕⊕©
LOWa
15 per 1000 28 per 1000
(6 to 126)
Organ system failure -
renal insuf f iciency re-
quiring support
Study populat ion OR 0.82
(0.34 to 1.98)
267
(4 RCTs)
⊕⊕©©
LOWb
92 per 1000 77 per 1000
(33 to 168)
Plasma pH - postopera-
t ive pH
Mean postoperat ive pH
was 7.32.
Mean postoperat ive pH
in intervent ion group
was 0.05 higher (0.04
to 0.07)
- 720
(12 RCTs)
⊕⊕⊕©
MODERATEc
Serum chloride (mmol/
L) - postoperat ive chlo-
ride
Mean postopera-
t ive chloride was 114.3
mmol/ L.
Mean postoperat ive
chloride in intervent ion
group was 6.77 mmol/
L lower (3.38 to 10.17)
- 530
(10 RCTs)
⊕⊕⊕©
MODERATEd
*The risk in the intervention group (and its 95% conf idence interval) is based on assumed risk in the comparison group and relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OR: odds rat io; RR: risk rat io.4
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GRADE Working Group grades of evidence.
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded -2. Data f rom 3 studies only with few events. All 3 studies have unclear risk of bias for outcome assessment.
Waters et al. also has unclear risk of report ing bias and attrit ion bias. Overall conf idence in the ef fect est imate is low.
bDowngraded -2. Half of studies included pat ients with the confounding ef fect of exist ing organ failure, i.e. part icipants
undergoing renal transplant for renal failure. All studies had unclear risk of detect ion bias. 2 studies had unclear risk of
report ing bias. 2 studies had unclear risk of attrit ion bias.
cDowngraded -1. Signif icant heterogeneity in methods, included part icipant characterist ics, and outcomes between studies.
Small numbers of part icipants in each trial.
dDowngraded -1. Signif icant heterogeneity in methods, included part icipant characterist ics, and outcomes between studies.
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B A C K G R O U N D
Description of the condition
Administration of intravenous fluids is a nearly universal practice
for patients undergoing major surgery who need to maintain in-
travascular volume at a time when that volume may be depleted
owing to preoperative dehydration, intraoperative haemorrhage,
or movement of fluid into a different physiological space. Intra-
venous fluids in these circumstances offer the advantages of being
relatively cheap and easily available and causing few side effects
as compared with blood transfusion. The ideal intravenous fluid
would allow splinting of the circulation for an adequate time to
replace missing plasma volume whilst not leading to adverse ef-
fects.
Intravenous fluids are manufactured with the addition of a mix-
ture of electrolytes to water (making a crystalloid solution), and
sometimes with the addition of a suspension of particles to water
(making a colloid solution). A wide variety of available fluid for-
mulations differ in two basic ways: first, by the different compo-
nent electrolytes that are in solution with water, which can inter-
act with the body’s internal equilibrium once infused; and second,
by the addition of a suspended non-soluble colloid material to
exert oncotic pressure. The colloid versus crystalloid debate has
been extensively explored, but the electrolyte formulation itself
has been less often examined (O’Connor 2001). In 2011, a series
of guidelines on administration of intravenous fluids were released
(GIFTASUP 2011). One key recommendation was that balanced
solutions should be used for fluid resuscitation and replacement to
avoid metabolic derangement. A recent consensus statement from
the International Fluid Optimization Group also recommended
the use of balanced crystalloids for low-risk patients undergoing
surgery of short duration (Navarro 2015).
Description of the intervention
Different intravenous solutions have been available for human use
for many years (Cosnett 1989). For the past half-century, themost
widely used fluids have been based on a 0.9% sodium chloride
solution (normal saline). Similarly, most colloids have been avail-
able only suspended in normal saline. This reliance on normal
saline has been due in large part to its ease of manufacture and
its ability to counteract effects of fluid loss - capabilities that have
been shown historically. Thus, saline-based fluids have remained
the standard of care when intravenous volume is required but ad-
ministration of blood or blood products is not needed.
The electrolyte composition of normal saline is significantly dif-
ferent from that of plasma given to replace it. This may cause elec-
trolyte imbalance, in particular, hyperchloraemicmetabolic acido-
sis (Prough 1996), as plasma is diluted with saline. An electrolyte
imbalance such as this alters the body’s internal milieu and has a
wide range of effects (Bellomo 2001; Kellum 2004).
How the intervention might work
Intravenous fluid formulations that closely match the constituents
of human plasma have been available for some years (Hartmann
1934). In particular, these fluids contain a physiological buffer
that helps to maintain the body’s acid-base balance. Other no-
table differences in the composition of these buffered fluids in-
clude variable quantities of other electrolytes, such as potassium,
magnesium, and calcium, which closely reflect the composition
of plasma. Several types of crystalloid and colloid solutions con-
tain this physiological buffer (Table 1). Over the past few years,
researchers have investigated and compared the effects of buffered
and non-buffered fluids by conducting in vitro (Roche 2006), an-
imal (Wilcox 1983), and healthy volunteer studies (Reid 2003;
Williams 1999).
We planned to perform several subgroup analyses to identify pa-
tients for whom optimal selection of fluids may be important.
Planned analyses involved (1) examining the effects of different
colloid fluid types among elderly versus younger patients on the
basis that younger patients may have greater physiological reserve;
and (2) assessing the ability of the body to compensate for effects
of different fluids among patients undergoing elective versus emer-
gency procedures on the basis that patients treated in an emer-
gency situation may have less capacity to deal with non-buffered
fluids, and among patients undergoing cardiac versus non-cardiac
surgery on the basis that cardiopulmonary bypass may have pro-
found effects on acid-base and electrolyte status.
Why it is important to do this review
Over the past decade, several published clinical trials have exam-
ined outcomes of surgery among adult patients, but these trials
differed in outcomes measured, case mix included, size of study
samples enrolled, and quality of evidence provided. Therefore, the
clinical effects of buffered versus non-buffered fluids among adult
surgical patients remain uncertain. This systematic review is the
first conducted to examine this topic.
O B J E C T I V E S
To review effects of perioperative intravenous administration of
buffered versus non-buffered fluids for plasma volume expansion
or maintenance, or both, on clinical outcomes in adults undergo-
ing all types of surgery.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only published randomized controlled trials (RCTs).
We considered unpublished studies and studies published only in
abstract format for inclusion if adequate information regarding
study methods and results could be obtained.
Types of participants
We included studies on adults (aged 16 years and over) receiving
intravenous fluids whilst undergoing any form of surgery.
Types of interventions
We included administration of intravenous fluids with and with-
out a buffer (bicarbonate or bicarbonate precursor buffer, such as
maleate, gluconate, lactate, or acetate) for the purpose of plasma
volume expansion or maintenance during the perioperative pe-
riod. To minimize confounding factors, we considered only tri-
als in which the sole difference between experimental and control
arms involved the presence or absence of a buffer in the fluid.
We excluded studies that compared crystalloids with colloids and
those that compared fluids with different colloid components.
However, we included trials with three or more arms that satisfied
the other inclusion criteria.
We included as much as possible data reported by trials with three
or more arms: If two groups could be combined, we attempted
to do so by using the statistical methods presented in Chapter 7
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
We defined the perioperative period as extending from two hours
before the start of surgery up to six hours after surgery or until
arrival to a postanaesthetic care unit. We included only studies
that used isotonic fluids (osmolarity 250 to 350 mmol/L) and a
broadly physiological concentration of sodium (120 to 160mmol/
L).
Types of outcome measures
Primary outcomes
1. Mortality (all time frames reported)
Secondary outcomes
1. Clinically significant organ system dysfunction as defined in
individual papers, including renal, pulmonary, hepatic,
gastrointestinal, coagulation, and central nervous system
2. Surrogate measures of organ system dysfunction including
urine output, serum creatinine, partial pressure of arterial carbon
dioxide (PaCO2), nausea, and vomiting
3. Blood loss or transfusion requirement
4. Serum measures of coagulation such as prothrombin time,
activated partial thromboplastin time, von Willebrand factor,
antithrombin 3 activity, fibrinogen, and thromboelastography
5. Biochemical or electrolyte disturbances including pH, base
excess, and serum bicarbonate, sodium, potassium, calcium, and
chloride
6. Postoperative hospital length of stay
7. Functional health status and quality of life measures as
described by identified papers
8. Cost
Search methods for identification of studies
Electronic searches
For this updated review, we searched the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL; 2016, Issue 6) in the
Cochrane Library (seeAppendix 1);MEDLINEviaOvidSP (1966
to June 2016) (see Appendix 2); Embase via OvidSP (1980 to June
2016) (see Appendix 3); and the Cumulative Index to Nursing
and Allied Health Literature (CINAHL) via EBSCOhost (1982
to June 2016) (see Appendix 4).
We reran the search in May 2017 and will deal with the one study
of interest when we update the review.
We did not impose language restrictions for the search criteria.
(In the original review, we searched to May 2011 (Burdett 2012).
We preserved topic search terms but updated filters for identifying
RCTs in accordance with theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). The initial search strategy
- used up to 2003 - is available in Appendix 5.)
Searching other resources
We handsearched relevant journals and conference abstracts not
previously handsearched by Cochrane Review groups and there-
fore not included in CENTRAL. For this update, we searched the
following conference abstracts for relevant studies published to
June 2016. (For the original review (Burdett 2012), we searched
from 1998 to 2010.)
1. American Society of Anesthesiologists (ASA).
2. International Anesthesia Research Society (IARS).
3. Society of Cardiovascular Anesthesiologists (SCA).
4. Society of Critical Care Medicine (SCCM).
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5. European Society of Intensive Care Medicine (ESICM).
6. American Thoracic Society (ATS).
7. European Association of Cardiothoracic Anesthesiologists
(EACTA).
8. International Symposium on Intensive Care and
Emergency Medicine (ISICEM).
9. American College of Surgeons (ACS).
10. Network for the Advancement of Transfusion Alternatives
(NATA).
11. Association of University Anesthesiologists (AUA).
12. Society of Thoracic Surgeons (STS).
13. European Society of Anesthesiologists (ESA).
14. American Society of Critical Care Medicine (ASCCM).
We checked the reference lists of all identified trials and reviews
and, when possible, contacted trial authors to ask if any studies
had been missed.
Data collection and analysis
Selection of studies
Five review authors (TG, EB, AR, SB, and PO) independently
identified appropriate studies after screening conference abstracts
and abstracts identified via electronic searches.
Data extraction and management
Two review authors (SB and PO) independently extracted study
characteristics and outcomes for each trial using a standardized
data extraction form. We resolved disagreements by consensus or
by consultation with a third review author (EB). We entered data
into Review Manager software (RevMan 5.3) and checked them
for accuracy. We attempted to contact study authors to obtain
further information, when necessary.
Assessment of risk of bias in included studies
Two independent review authors (SB and PO) assessed risk of
bias of included studies. When details on published manuscripts
were not available, we attempted to contact study authors directly
for clarification. When data were published in graphical form, we
converted results to numerical form by enlarging and measuring
the diagrams. We assessed potential risk of bias for each study
using the Cochrane ’Risk of bias’ tool (Higgins 2011).
For full details of included studies, see the Characteristics of
included studies table. We discussed in the Results section the
results of our ’Risk of bias’ assessment. We performed sensitivity
analyses to determine whether treatment effects on primary and
secondary outcomes were the same when we assessed only stud-
ies that used adequate methods of randomization, allocation con-
cealment, and study blinding, and provided a description of with-
drawals.
Measures of treatment effect
When appropriate, we pooled trial data. We calculated the treat-
ment effect across all trials using the Cochrane statistical package
Review Manager 5.3 (RevMan 5.3). We calculated mean differ-
ences (MDs) with 95% confidence intervals (CIs) using an inverse
variance method for continuous variables. When outcome data
were skewed to the extent that the mean divided by the standard
deviation (SD) was less than 1, indicating strong evidence of a
skewed distribution (Altman 1996), and when only means and
SDs on the un-logged scale were available, we performed statis-
tical manipulation as described in Higgins 2008 and Jones 2011
by transforming raw means and SDs to the log scale. We then
analysed data on the log scale using a generic inverse variance
method available in RevMan 5.3. We exponentiated pooled MDs
between buffered and non-buffered groups on the log scale to de-
termine the ratio of geometric means of the variable on the un-
logged scale, which quantifies the relative difference in the origi-
nal untransformed outcome variable between buffered and non-
buffered groups as a percentage difference, to aid interpretation
(Bland 1996). For dichotomous variables, we used the Mantel-
Haenszel method with odds ratios (ORs) for common outcomes
(> 5%) and Peto OR for rare outcomes (< 5%).
Unit of analysis issues
When studies included more than two groups, we merged data
into groups when the intervention was equivalent. Some studies
included groups of participants who did not receive the interven-
tions of interest and excluded these groups from analyses.
Dealing with missing data
We contacted the authors of included trials to obtain required
data that were missing from manuscripts and to discover missing
information about methodological properties (randomization, al-
location concealment, blinding) of these trials.
Assessment of heterogeneity
We quantified the degree of heterogeneity in trial results using
the I² statistic, which expresses the percentage of total variation
observed between studies due to differences between studies rather
than to sampling error (Higgins 2011). We assumed significant
heterogeneity when I² was 40% or greater. When heterogeneity
was significant, we used random-effects models. When I² was less
than 40%, we used a fixed-effect model.
Assessment of reporting biases
We planned to assess the presence of possible publication bias and
heterogeneity for the primary outcome by using funnel plot anal-
ysis (Egger 1997; Sterne 2001). In the case of suspected publica-
tion bias, we intended to use the trim and fill method to assess
8Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical
procedures (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the impact of potential publication bias and the robustness of the
estimate (Gilbody 2000; Sutton 2000).
Data synthesis
We used Review Manager software (RevMan 5.3) to conduct our
meta-analyses when it was reasonable to assume that studies were
estimating the same underlying treatment effect. When clinical
heterogeneity was sufficient to suggest that the underlying treat-
ment effect was not clinically meaningful, we did not combine
trials, for example, when trials were examining insufficiently simi-
lar populations. We tested dichotomous outcomes using ORs and
95% CIs, and continuous outcomes using MDs between groups
and 95%CIs.We assumed P < 0.05 to be of statistical significance.
Subgroup analysis and investigation of heterogeneity
To explore sources of heterogeneity between studies on those oc-
casions when it was possible to do so, we planned to perform sub-
group analyses for the primary outcome by colloid categories, age
groups (≤ 65 years, > 65 years), elective and emergency surgery,
cardiac and non-cardiac surgery, fluids with and without calcium,
fluids with and without magnesium, fluids with and without glu-
cose, and fluids containing bicarbonate and fluids containing a bi-
carbonate precursor buffer. However, this was not possible because
we found insufficient studies reporting our anticipated primary
outcome of mortality at all time frames.
Sensitivity analysis
We planned to perform sensitivity analysis for the primary out-
come to explore robustness of results by study quality, in particular
in the presence or absence of adequate randomization, allocation
concealment, study blinding, and other bias, as shown in the risk
of bias assessment, when numbers of trials were adequate for us to
do so. Second, when applicable, we planned to examine the results
of skewed data using un-logged data for comparisons.
’Summary of findings’ table and GRADE
We judged the quality of evidence and generated a ’Summary of
findings’ table using GRADEproGDT (GRADEproGDT 2015;
Guyatt 2011a).We based our assessment of the quality of evidence
on assessments of imprecision, inconsistency, risk of bias, and in-
directness for all studies reporting specific outcome measures. We
considered the starting point to be ’high quality’ because of the
randomized design of all included studies. We downgraded qual-
ity by one or two levels on the basis of assessment of GRADE
criteria and assessment of the methodological quality and design
of included studies. The ’Summary of findings’ table in this re-
view presents mortality, organ system failure, postoperative pH,
and postoperative chloride. Mortality was the primary outcome
in this review; we therefore have presented these data in the ta-
ble.We have reported organ system failure, postoperative pH, and
postoperative chloride as secondary outcomes of interest.
R E S U L T S
Description of studies
Results of the search
See Figure 1.
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Figure 1. Prisma study flow diagram.We reran the search in May 2017. We found one study of interest. We
added this study to a list of ‘Studies awaiting classification’ and will incorporate it into formal review findings
during the review update.
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We identified 3546 citations through database searches, manual
searches, citation reviews, and contactwith experts. After screening
by title, then by abstract, we obtained full-paper copies of 41
citations that were potentially eligible for inclusion in the review.
We analysed each citation by hand and included 19 publications
of 18 trials or comparisons.
We reran the search inMay 2017,which revealed 432newcitations
and one potential new study of interest. We added this potential
new study of interest to a list of ‘Studies awaiting classification’ and
will incorporated it into formal review findings when we prepare
the review update.
Included studies
Populations
Nineteen studies met our inclusion criteria for study design, par-
ticipants, and interventions. We identified a total of 1096 partic-
ipants, of whom 563 received buffered fluids and 533 received
non-buffered fluids. Two papers reported one trial, but reported
outcomes were different in the two papers and showed no over-
lap, so we considered these publications separately (Martin 2002;
Moretti 2003). We took care to ensure that participants were not
counted twice. All included trials were fully published in peer-
reviewed journals. We were unable to identify any unpublished
studies suitable for inclusion in our review. We have listed addi-
tional study characteristics in Table 2 and have described these
studies under Characteristics of included studies.
Five studies included patients with renal transplants (Hadimioglu
2008; Khajavi 2008; Kim 2013; Nuraei 2010; O’Malley 2005).
As this population was different from the population undergoing
other perioperative procedures, we performed sensitivity analysis,
when possible, for renal outcomes such as intraoperative urine
output. Further, data described in Analysis 1.11.1 and Analysis
1.11.2 were significantly skewed to the extent that SDs divided
by means were less than 1 for all included studies and SDs were
comparable with mean values. We transformed data according to
the third method described byHiggins, which is a suitable method
for rendering skewed data appropriate for meta-analysis, and we
inserted the transformed data into RevMan for analysis (Higgins
2008; RevMan 5.3).
Interventions
Interventions varied between studies. Of 19 included publica-
tions, 13 used only crystalloids in their experimental and con-
trol arms (Chin 2006; Hadimioglu 2008; Heidari 2011; Khajavi
2008; Kim 2013; McFarlane 1994; Nuraei 2010; O’Malley 2005;
Scheingraber 1999; Song 2015; Takil 2002; Walsh 1983; Waters
2001). Of these studies, nine compared lactated Ringer’s solution
versus normal saline (Chin 2006; Heidari 2011; Khajavi 2008;
Nuraei 2010; O’Malley 2005; Scheingraber 1999; Takil 2002;
Walsh 1983; Waters 2001), and four compared Plasmalyte 148
versus normal saline (Hadimioglu 2008; Kim 2013; McFarlane
1994; Song 2015). One trial included two buffered crystalloid
arms, each consisting of 30 participants (Plasmalyte 148 and lac-
tated Ringer’s solution), and one normal saline arm of 30 partic-
ipants (Hadimioglu 2008). We combined the two buffered arms
numerically using the statistical methods described in Chapter 7
of the Cochrane Handbook for Systematic Reviews of Interventions
(Version5.1;Higgins 2011), so in effectwe compared one buffered
arm of 60 participants consisting of combined Plasmalyte and lac-
tatedRinger’s arms versus the non-buffered armof 30 participants.
Six publications described five trials that used colloid solutions in
their experimental and control arms (Base 2011; Gan 1999; Kulla
2008; Martin 2002; Moretti 2003; Wilkes 2001). All compared a
buffered hydroxyethyl starch (HES) solution versus a non-buffered
HES solution. Of these, four trials used high molecular weight
(MW) HES (Gan 1999; Martin 2002; Moretti 2003; Wilkes
2001), and two used low MW HES (Base 2011; Kulla 2008).
All trials used lactate as the buffering agent in the group given
buffering fluids except one (Kulla 2008), which used a fluid con-
taining acetate.
Of 19 identified publications, only seven had protocols that com-
pared completely buffered versus completely non-buffered flu-
ids (Chin 2006; Heidari 2011; McFarlane 1994; Nuraei 2010;
Scheingraber 1999; Walsh 1983; Wilkes 2001). The other reports
described trials that administered a combination of buffered and
non-buffered fluids in one armof the study (Base 2011;Gan 1999;
Hadimioglu 2008; Khajavi 2008; Kim 2013; Kulla 2008; Martin
2002; Moretti 2003; O’Malley 2005; Song 2015; Takil 2002;
Waters 2001). Hence these trials compared a partially buffered
fluid regimen versus a totally buffered fluid regimen, although
only one trial reported this after collecting study data (Hadimioglu
2008). More details appear in Table 2.
Outcomes
Outcomes obtained from these trials were similar in theme but
were heterogeneous in units, statistical reporting methods, and
time scales; as such, not all were suitable for meta-analysis. When
practical, we sought unpublished data in an attempt to rectify
this. Our attempts were successful in some cases, as some trial
authors provided outcome information beyond published details
(Base 2011; Gan 1999;Martin 2002;Moretti 2003;Waters 2001;
Wilkes 2001).
Data reported were heterogeneous. Data potentially of interest to
this review but reported only in single studies and therefore not
suitable for numerical analysis are listed as orphan outcomes in
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Table 3. In particular, the timing of reported endpoints of these
trialswas heterogeneous for the first 48hours postoperatively.Only
three studies described biochemical data beyond this time point
(Khajavi 2008; Nuraei 2010; O’Malley 2005). We synthesized
these data for analysis by dividing them into the following time
categories.
1. Immediately postoperatively: This category consisted of the
first reported postoperative data unless stated otherwise in the
trial.
2. Five to 10 hours postoperatively: All studies that included
data within these times are included here.
3. First postoperative day (POD1): This category included all
data described as reported 12 to 24 hours postoperatively or on
postoperative day one.
We included additional time categories as appropriate.
Funding sources
Five of the included trials received funding from pharmaceutical
companies that manufactured an intervention examined in the
trial (Base 2011; Gan 1999; Martin 2002; Moretti 2003; Wilkes
2001). Each included study appropriately disclosed all funding.
Excluded studies
We excluded 22 clinical studies for reasons described in the
Characteristics of excluded studies table (Bennett-Guerrero 2001;
Bick 1995; Boldt 1993; Boldt 2002a; Boldt 2002b; Boldt 2007;
Boldt 2009; Boldt 2010; Campbell 1990; Choi 2010; Evans
2003; Javnrin 1980; Kaplan 2001; Krebbel 2014; Lowery 1967;
Protsenko 2009; Reid 2003; Roche 2006; Ruttman 1996; Walker
2001; Williams 1999; Young 2015).
Studies awaiting classification
We identified one study awaiting classification for the updated
review in the May 2017 search (Pfortmueller 2017). Please refer
to the Characteristics of studies awaiting classification table for
details.
Of two studies awaiting classification from the previous review
(Burdett 2012), we included one in this updated review following
translation into English (Nuraei 2010) and we excluded the other
(Choi 2010).
Ongoing studies
We identified one ongoing study on the ClinicalTrials.gov trials
registry (NCT02565420). This study is currently recruiting par-
ticipants for a trial of saline versus Ringer’s lactate. The primary
outcome measure is major postoperative complications, and the
study has an estimated completion date of 2022.
Risk of bias in included studies
Allocation
All trials were randomized. Fifteen trials provided details about
allocation sequence generation and were considered to be at low
risk of bias (Base 2011; Chin 2006; Gan 1999; Hadimioglu 2008;
Heidari 2011; Khajavi 2008; Kim 2013; Martin 2002; Moretti
2003; Nuraei 2010; O’Malley 2005; Song 2015; Takil 2002;
Waters 2001; Wilkes 2001). Generally, participant numbers in
these trials were low, with four trials enrolling fewer than 20 par-
ticipants in each arm (McFarlane 1994; Scheingraber 1999; Takil
2002; Walsh 1983).
Twelve studies mentioned the method of allocation concealment
used andwe considered them tobe at low risk of selectionbias (Base
2011; Chin 2006; Gan 1999; Khajavi 2008; Kim 2013; Martin
2002; Moretti 2003; O’Malley 2005; Song 2015; Takil 2002;
Waters 2001; Wilkes 2001). Two studies showed no evidence of
allocation concealment, and we considered them to be at high risk
of bias for this criterion (McFarlane 1994; Walsh 1983).
We have summarized this information in Figure 2 and Figure 3.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
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Figure 3. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Blinding
All included studies were randomized trials. A total of 16 studies
referred to blinding or double-blinding in their design (Base 2011;
Chin 2006; Gan 1999; Hadimioglu 2008; Heidari 2011; Khajavi
2008; Kim 2013; Kulla 2008;Martin 2002;Moretti 2003; Nuraei
2010; O’Malley 2005; Scheingraber 1999; Song 2015; Waters
2001; Wilkes 2001); hence, we considered these studies to be at
low risk of performance and detection bias. Only three studies
made no reference to blinding, and we considered them to be at
high risk for potential bias (McFarlane 1994; Takil 2002; Walsh
1983). We did not consider the included studies to be at risk for
any other potential performance or detection bias.
Incomplete outcome data
Investigators lost few participants to follow-up and gave reasons
for all lost participants. Researchers performed intention-to-treat
analysis, when possible, except in one case, when the trial excluded
three participants after randomization because they met an exclu-
sion criterion preoperatively (O’Malley 2005). The manuscript
does not detail which group each participant was excluded from,
and investigators analysed the data after these participants were
removed. We judged only one trial to be at high risk of attrition
bias because a high proportion of participants dropped out of the
trial owing to administration of non-protocol intravenous fluids
(Chin 2006).
Selective reporting
We did not detect reporting bias and therefore categorized all
studies as low risk.
Other potential sources of bias
Of note, pharmaceutical companies that manufactured an inter-
vention of interest funded five of the included studies (Base 2011;
Gan 1999; Martin 2002; Moretti 2003; Wilkes 2001). Although
each study clearly disclosed these funding sources, we considered
these studies to be at unclear risk of bias. Two other studies did not
report sufficient detail about outcomes of interest, and we there-
fore considered them to be at unclear risk of bias (Heidari 2011;
Kulla 2008).
Effects of interventions
See: Summary of findings for the main comparison Buffered
versus non-buffered crystalloid intravenous fluid for adults
undergoing any form of surgery
All included studies reported at least one outcome of interest, as de-
scribed above in Types of outcome measures. Reported outcomes
varied a great deal between included trials, and some study authors
expressed data in ways that made them unsuitable for statistical
synthesis.
Primary outcome
Mortality
Three clinical trials with a total of 267 participants reported mor-
tality (Base 2011: Gan 1999; Waters 2001). Mortality was low
in both groups: 2.9% (4/136) in the buffered group and 1.5%
(2/131) in the non-buffered group. Pooling of these limited data
suggests no important mortality differences between groups (Peto
OR 1.85, 95% CI 0.37 to 9.33; I² = 0%; Analysis 1.1).We down-
graded the quality of evidence from high to low owing to impre-
cision of trial results due to small sample sizes, wide confidence
intervals, and methodological variability between studies. Studies
reporting mortality presented few events, and we consider all three
studies to be at unclear risk of bias for outcome assessment. One
of these studies is also at unclear risk of reporting bias and attrition
bias (Waters 2001). Overall confidence in the effect estimate is
low.
Secondary outcomes
Organ system failure
Four trials with a total of 267 participants reported on renal insuf-
ficiency leading to the requirement for renal replacement therapy
(Hadimioglu 2008; Kim 2013; O’Malley 2005; Waters 2001).
Data show lower risk of renal insufficieny requiring renal support
with the use of buffered fluids (4.7% (11/148) vs 9.2% (11/119)),
but we have little confidence that this difference is real (OR 0.82,
95% CI 0.34 to 1.98; I² = 0%; Analysis 1.2). We rated the quality
of evidence as low because of limitations in study design and im-
plementation. Three of these studies included participants with
the confounding effect of pre-existing organ failure (i.e. partici-
pants undergoing renal transplant for renal failure) (Hadimioglu
2008; Kim 2013; O’Malley 2005).
The single study that examined respiratory failure enrolled 81 par-
ticipants and reported four cases (9.3%) of postoperative respira-
tory failure in the buffered group and one case (2.6%) in the non-
buffered group (Base 2011). Authors of the primary study offered
no comment on reported differences between groups. We did not
subject these data to further analysis, and we listed this outcome
as an orphan outcome in Table 3.
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No trials specified any outcomes regarding failure of other organ
systems (cardiac, gastrointestinal, or neurological).
Surrogate measures of organ system dysfunction (urine
output, serum creatinine, PaCO2, nausea and vomiting)
Urine output
Eight trials with a total of 459 participants reported intraoperative
urine output during the intraoperative period and on the first post-
operative day(Gan 1999; Kulla 2008; Kim 2013; O’Malley 2005;
Scheingraber 1999; Takil 2002;Waters 2001;Wilkes 2001).Mean
urine output reported intraoperativelywas 872mL for the buffered
fluid group and 799 mL for the non-buffered fluid group. Data
show no important differences between groups. The mean differ-
ence was 6.1 mL higher in the buffered group (95% CI -128.41 to
140.61; I² = 49%). We encountered significant heterogeneity for
this analysis (I² = 49%); therefore we calculated this comparison
using a random-effects model (Analysis 1.3).
Four studies included renal transplant patients, and we believe that
this group represented a different population with abnormal renal
function and may not be comparable with the standard periop-
erative participants included in other studies (Khajavi 2008; Kim
2013; Nuraei 2010; O’Malley 2005). We performed sensitivity
analysis while excluding these studies, which confirmed no impor-
tant differences between groups for intraoperative urine output,
with a mean difference of 10 mL (95% CI -147 to 167; I² = 57%;
Analysis 1.3). We were unable to perform a subgroup analysis of
intraoperative urine output for these renal transplant participants,
as only one study reported this outcome (O’Malley 2005), and
another study reported on urine output on the first operative day
(Hadimioglu 2008).
Two trials with a total of 151 participants reported urine output
by the first postoperative day (Hadimioglu 2008; Kulla 2008).We
were unable to pool these data owing to clinical heterogeneity be-
tween studies (Analysis 1.3). One study enrolled renal transplant
patients, and these participants had a large amount of urine output
on the first postoperative day (Hadimioglu 2008). Once again,
this patient group may not reflect perioperative participants in the
other study (Kulla 2008). We performed a subgroup analysis of
data from the only two studies that reported intraoperative urine
output in participants undergoing renal transplant surgery (Kim
2013;O’Malley 2005). Pooled outcomes for both studies hadwide
95% confidence intervals and did not indicate an important dif-
ference between groups;MD was 58.26 mL greater with buffered
solutions (95% CI -446.7 to 563.21; P = 0.82; I² = 42%).
One study reported 24-hour urine output in mL/kg body weight,
and we were unable to get further information from trial authors
(Base 2011). A second study reported intraoperative urine output
in mL/kg/h, and we were unable to obtain further information
from these authors as well (Song 2015).
Postoperative serum creatinine change
Two trials with a total of 113 participants reported postoperative
serum creatinine change (Waters 2001; Wilkes 2001). Data show
no important differences in the postoperative creatine change be-
tween buffered and non-buffered groups; the mean difference was
6.96µmol/L lower in the buffered group (95%CI -27.42 to 13.50;
I² = 89%). Owing to significant heterogeneity (I² = 89%), we used
random-effects models for this comparison (Analysis 1.4).
Postoperative day one creatinine change
Two trials with a total of 113 participants reported postopera-
tive day one creatinine change (Waters 2001; Wilkes 2001). Data
show no important differences in postoperative day one creatinine
change between groups. The mean difference was 4.94 µmol/L
lower in the non-buffered group (95% CI -5.91 to 15.78; I² =
12%; Analysis 1.4).
Postoperative absolute creatinine values
Three trials with a total of 235 participants reported postopera-
tive creatinine (Kulla 2008; Nuraei 2010; Waters 2001). One trial
reported postoperative creatinine in participants undergoing re-
nal transplant surgery (Nuraei 2010). In this study, investigators
reported that mean creatinine was 530 µmol/L in the buffered
fluid group and 460 µmol/L in the non-buffered group. Data
show no important differences between groups. Trials conducted
in non-renal transplant participants reporting absolute creatinine
reported that mean creatinine was 76.72 µmol/L in the buffered
fluid group and 79.53 µmol/L in the non-buffered group. Overall,
for all three trials together, the MDwas -1.31 µmol/L lower in the
non-buffered group (95% CI -9.30 to 6.68; I² = 71%; Analysis
1.5).
Three trials with a total of 211 participants reported postoperative
day one creatinine (Hadimioglu 2008; Kim 2013; Kulla 2008).
Two studies enrolled renal transplant patients (Hadimioglu 2008;
Kim 2013). Data show a mean difference 6.26 µmol/L lower in
the buffered group (95% CI -21.17 to 8.64; I² = 0%; Analysis
1.5).
Four trials with a total of 301 participants reported postopera-
tive day three creatinine (Hadimioglu 2008; Khajavi 2008; Nuraei
2010; O’Malley 2005). All four studies enrolled renal transplant
patients. Investigators reported mean postoperative day three cre-
atinine of 172.5 µmol/L in the buffered group and 167.5 µmol/
L in the non-buffered group. Data show no important differences
between groups; the MD was 0.47 µmol/L lower in the buffered
group (95% CI -30.12 to 29.19; I² = 0%; Analysis 1.5).
Four trials with a total of 309 participants reported postopera-
tive week one serum creatinine (Hadimioglu 2008; Kim 2013;
Nuraei 2010;O’Malley2005). All four studies enrolled renal trans-
plant patients. Mean postoperative week one serum creatinine was
131.1 µmol/L in the buffered group and 114.2 in the non-buffered
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group. Data show no important differences between groups; MD
was 5.36 µmol/L lower in the buffered group (95% CI -25.29 to
14.56; I² = 0%; Analysis 1.5).
One trial with a total of 51 participants reported six-month serum
creatinine of 132.64 (± 53.84) µmol/L in the buffered group and
132.6 (± 35.3) µmol/L in the non-buffered group (O’Malley
2005). Trial authors reported no clear differences between groups.
We did not attempt to perform analysis for this comparison (Table
3).
Postoperative creatinine clearance
Three trials with a total of 222 participants reported postopera-
tive creatinine clearance (Base 2011; Hadimioglu 2008; O’Malley
2005). Results show no important differences in this outcome be-
tween groups; MD was 12.61 mL/min higher in the non-buffered
group (95% CI -2.31 to 27.54; I² = 0%; Analysis 1.6).
Partial pressure of arterial carbon dioxide (PaCO²)
Seven trials with a total of 446 participants reported postoperative
PaCO² at two time points (Hadimioglu 2008; Kim 2013; Kulla
2008;Nuraei 2010; Song 2015; Takil 2002;Wilkes 2001). Results
showmean PaCO² of 34.9 mmHg in the buffered fluid group and
35.0 mmHg in the non-buffered fluid group. PaCO was higher
in the buffered group (MD 1.05 mmHg, 95% CI 0.15 to 1.94;
I² = 0%; Analysis 1.7).
Two trials with a total of 91 participants reported postoperative
day one PaCO² of 41 mmHg in the buffered fluid group and 37.7
mmHg in the non-buffered fluid group (Kulla 2008; Takil 2002).
PaCO was higher in the buffered group (MD 3.3 mmHg, 95%
CI 2.03 to 4.64; I² = 0%; Analysis 1.7).
Postoperative vomiting
Three trials reported 21 episodes of postoperative vomiting in 84
participants (25%) in the buffered fluid group and 28 episodes
of postoperative vomiting in 84 participants (33%) in the non-
buffered fluid group (Heidari 2011; Moretti 2003; Wilkes 2001).
Data show no clear differences between groups (OR 0.66, 95%
CI 0.34 to 1.30; I² = 20%; Analysis 1.8).
One trial with a total of 60 participants reported that 22 partici-
pants (73%) in the buffered group and 14 participants (47%) in
the non-buffered group had experienced nausea postoperatively
(Moretti 2003). The authors of this study did not perform sta-
tistical analysis of differences between these groups. We did not
attempt numerical analysis for this orphan outcome (Table 3).
One trial with a total of 47 participants reported differences be-
tween PaCO outcomes measured by gastric tonometry and ar-
terial blood gas analysis (Pg−aCO ) of 0.9 ± 1.1 kPa for the
buffered group and 1.7 ± 0.5 kPa for the non-buffered group (P =
0.04) (Wilkes 2001). We did not attempt numerical analysis for
this orphan outcome (Table 3).
Blood loss and transfusion requirement
Blood loss
Thirteen trials reported on intraoperative blood loss (mL) (Base
2011; Gan 1999; Khajavi 2008 Kulla 2008; Martin 2002;
McFarlane 1994; O’Malley 2005; Scheingraber 1999; Song 2015;
Takil 2002; Walsh 1983; Waters 2001; Wilkes 2001). Two studies
reported estimated blood loss in mL/kg and could not be included
in the analysis because they did not report patient weight (Base
2011;McFarlane 1994). Analysis of data from the other nine stud-
ies with a total of 576 participants revealed 287 in the buffered
fluid groups and 287 in the non-buffered fluid groups. Clinical
heterogeneity between these trials was great, with two trials re-
porting less than 400 mL of estimated blood loss (O’Malley 2005;
Walsh 1983) and two trials reporting estimated blood loss of 2 L or
more (Takil 2002; Waters 2001). These findings reflect the type of
surgery conducted, showing relatively large amounts of blood loss
for abdominal aortic aneurysm repair (Waters 2001) and during
major spinal surgery (Takil 2002). Results made it unlikely that
any analysis would yield a clinically significant result if the group
was analysed as a whole.
We performed subgroup analysis to attempt to reduce clinical het-
erogeneity by arbitrarily grouping trials with less than 1000 mL of
blood loss and those with blood loss of 1000 mL or more (Analysis
1.9). Trials reporting blood loss less than 1000 mL (five studies
with 202 participants) reported no important differences between
group sand showed mean difference in intraoperative blood loss
that was 5.90 mL higher in the buffered group (95% CI -45.18
to 56.99; I² = 0%) (Khajavi 2008; Kulla 2008; O’Malley 2005;
Scheingraber 1999; Walsh 1983). Trials reporting blood loss was
of 1000 mL or more (six studies with 374 participants) also re-
ported no important differences in blood loss between groups and
showed mean difference in intraoperative blood loss that was 173
mL lower in the buffered group (95% CI -438.8 to 92.7; I² =
13%; Analysis 1.9) (Gan 1999; Martin 2002; Song 2015; Takil
2002; Waters 2001; Wilkes 2001).
One trial with a total of 61 participants reported estimated blood
loss during the first postoperative day (Kulla 2008). Trial authors
reported no important differences in blood loss between buffered
(289 ± 325mL) and non-buffered groups (309 ± 250 mL).We did
not include these data in the analysis and listed this as an orphan
clinical outcome in Table 3.
Intraoperative red cell transfusion
Four trials with a total of 152 participants reported on the
quantity of intraoperative red cell transfusion (O’Malley 2005;
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Scheingraber 1999; Takil 2002; Wilkes 2001). Data show no im-
portant differences in the quantity of red cells transfused between
individuals given buffered fluids and those given non-buffered so-
lutions. The mean difference was 29 mL less in the buffered fluid
group (95% CI -117 to 59; I² = 28%; Analysis 1.10).
Other blood products given
Outcomes for this comparison include data that were significantly
skewed. Therefore, we first transformed data according to the
third method described in an article written by Higgins (Higgins
2008) and subsequently analysed them using the inverse vari-
ance method. Estimated effect sizes and associated 95% CIs con-
sequently quantified the relative difference in the original un-
transformed outcome variable between groups (ratio of geometric
means), expressed as a percentage.
Platelet transfusion
Data from four studies with a total of 293 participants that de-
tailed the volume of platelets transfused in each arm were suit-
able for analysis (Gan 1999; Martin 2002; Waters 2001; Wilkes
2001). Analysis revealed an important difference between treat-
ment groups in the volume of platelets transfused. The pooled
estimate showed that 242% (log ratio 1.23) more platelets were
transfused (mL) in the non-buffered group than in the buffered
group (95% CI 24.61% to 848.77%; I² = 0%; Analysis 1.11).
Fresh frozen plasma given
Three studies with a total of 233 participants reported the volume
of fresh frozen plasma given (Gan 1999; Waters 2001; Wilkes
2001). Results revealed no important differences between groups.
The pooled estimate showed that 60% (log ratio 0.47) more fresh
frozen plasma (mL) was given in the non-buffered group, but
this finding was not statistically significant (95% CI -30.93% to
266.93%; I² = 0%; Analysis 1.11).
None of these trials reported administration of any other blood
product, such as cryoprecipitate or blood factor concentrate.
Serum measures of coagulation
Measures included activated partial thromboplastin time, pro-
thrombin time, Factor VIII, von Willebrand factor, ristocetin co-
factor, and thromboelastography, antithrombin 3 activity, fibrino-
gen and thromboelastogram.
Two studies with a total of 181 participants reported serum acti-
vated partial thromboplastin time (APTT) at a series of time in-
tervals (Gan 1999; Kulla 2008). APTT at end of surgery was 35.5
seconds in the buffered fluid group and 34.6 seconds in the non-
buffered fluid group, showing no important differences between
groups. The mean difference was 1 second higher in the buffered
group (95% CI -1.82 to 3.58; I² = 0%; Analysis 1.12). One trial
involving 62 participants reported that APTT on postoperative
day one was 35 ± 4 seconds in the buffered group and 34 ± 4
seconds in the non-buffered group (Kulla 2008). This difference
was not statistically significant, and we did not subject these data
to numerical analysis (Table 3).
Only one trial reported prothrombin time (PT) (Gan 1999). At
end of surgery, PT was 16 ± 4 seconds in the buffered group and
17 ± 7 seconds in the non-buffered group, showing no important
differences between groups. We did not subject these data to nu-
merical analysis (Table 3).
Two trials with a total of 181 participants reported postoperative
Factor VIII (Gan 1999; Kulla 2008) levels of 92.8 IU/L in the
buffered group and 122.4 IU/L in the non-buffered group. Data
show an important difference between groups, with a mean dif-
ference 29.6 IU/L lower in the buffered group (95% CI -46.2 to
-12.9; I² = 0%; Analysis 1.13). One trial reported postoperative
Factor VIII levels 5 to 10 hours postoperatively and on the first
postoperative day (Kulla 2008). Data show no important differ-
ences between groups. We did not analyse these data and listed
this as an orphan outcome in Table 3.
Two trials with a total of 181 participants reported serum levels
of von Willebrand factor (vWF) of 121.1 IU/L in the buffered
fluid group and 152.5 IU/L in the non-buffered fluid group (Gan
1999; Kulla 2008). Results show an important difference between
groups, with a mean difference 31.4 IU/L lower in the buffered
fluid group than in the non-buffered fluid group (95% CI -47.7
to -15.1; I² = 0%; Analysis 1.13).
Only one trial with a total of 62 participants reported ristocetin
cofactor (Kulla 2008). Five to 10 hours postoperative and post-
operative day one ristocetin cofactor levels showed no important
differences between groups. We did not analyse these data and
listed this as an orphan outcome in Table 3.
Three trials reported thromboelastographic (TEG) data (Gan
1999; Martin 2002; Song 2015). Two studies reported postoper-
ative TEG data graphically (Gan 1999; Martin 2002). Therefore
we did not subject this measure to meta-analysis.
Serum biochemical or electrolyte disturbances
Measures included pH, base excess, serum bicarbonate, glucose,
chloride,sodium, potassium, lactate, and calcium.
pH
Twelve studies with a total of 720 participants reported postopera-
tive pH (Base 2011; Hadimioglu 2008; Khajavi 2008; Kim 2013;
Kulla 2008; Nuraei 2010; O’Malley 2005; Scheingraber 1999;
Song 2015; Takil 2002; Waters 2001; Wilkes 2001). Reporting
was heterogeneous with different time intervals. Mean postopera-
tive pH was 7.38 in the buffered fluid group and 7.32 in the non-
buffered fluid group. Data show that postoperative pH was 0.05
units lower (95%CI -0.04 to -0.07; I² = 61%) in the non-buffered
18Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical
procedures (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
fluid group than in the buffered group - an important difference
between groups. However, we downgraded the quality of this ev-
idence by one level to moderate because we noted a significant
degree of heterogeneity. Two trials with a total of 91 participants
reported pH on postoperative day one (Kulla 2008; Takil 2002).
Results show no important differences between groups; MD was
0.01 units lower in the non-buffered fluid group (95% CI -0.00
to 0.03; I² = 0%; Analysis 1.14).
Base excess
Investigators reported this outcome at various time intervals. Nine
studies with a total of 459 participants reported postoperative base
excess of -1.65 mmol/L in the buffered fluid group and -5.02
mmol/L in the non-buffered fluid group (Hadimioglu 2008; Kim
2013; Kulla 2008; McFarlane 1994; Scheingraber 1999; Song
2015; Takil 2002; Waters 2001; Wilkes 2001). Data show an im-
portant difference between groups, with MD 3.51 mmol/L lower
in the non-buffered fluid group than in the buffered fluid group
(95%CI 2.61 to 4.41).We noted statistical heterogeneity between
trials (I² = 70%); therefore, we calculated this comparison using a
random-effects model (Analysis 1.15).
Three studies with a total of 138 participants reported base ex-
cess on postoperative day one of -1.07 mmol/L in the buffered
fluid group and -3.55 mmol/L in the non-buffered fluid group
(Kulla 2008; Takil 2002; Wilkes 2001). Data show an important
difference between groups, with MD 2.48 mmol/L lower in the
non-buffered fluid group (95% CI 1.61 to 3.36; I² = 0%; Analysis
1.15).
Serum bicarbonate
Seven studies with a total of 478 participants reported postopera-
tive serum bicarbonate of 21.6mmol/L in the buffered fluid group
and 18.6 mmol/L in the non-buffered fluid group (Hadimioglu
2008; Kim 2013; O’Malley 2005; Scheingraber 1999; Song 2015;
Takil 2002; Waters 2001). Results show an important difference
between groups, withMD3.14mmol/L lower in the non-buffered
group (95% CI 2.30 to 3.98). We noted significant statistical het-
erogeneity between trials (I² = 59%); therefore, we calculated this
comparison using a random-effects model (Analysis 1.16).
Serum glucose
Three trials reported postoperative serum glucose of 6.0 mmol/
L for both buffered and non-buffered groups, showing no mean
differences between groups (95% CI -0.29 to 0.29; I² = 0%;
Analysis 1.17) (Chin 2006; Waters 2001; Wilkes 2001).
Serum chloride
Ten studies with a total of 530 participants reported postop-
erative serum chloride of 107.5 mmol/L in the buffered fluid
group and 114.3 mmol/L in the non-buffered fluid group at this
time point (Base 2011; Hadimioglu 2008; Kulla 2008; McFarlane
1994;O’Malley 2005; Scheingraber 1999; Song 2015;Takil 2002;
Waters 2001; Wilkes 2001). Data show an important difference
between groups, with MD -6.77 mmol/L higher in the non-
buffered fluid group (95% CI -10.17 to -3.38). We noted statis-
tical heterogeneity between trials (I² = 97%); therefore, we cal-
culated this comparison using a random-effects model (Analysis
1.18). In light of this heterogeneity, we downgraded the quality
of evidence to moderate because of significant inconsistency.
Five studies with a total of 258 participants reported mean serum
chloride on the first postoperative day of 105.7 mmol/L in the
buffered fluid group and 114.4 mmol/L in the non-buffered
fluid group (Hadimioglu 2008; Kim 2013; Kulla 2008; Takil
2002;Wilkes 2001). Data show an important differences between
groups, with MD -8.48 mmol/L higher in the non-buffered fluid
group (95% CI -15.88 to -1.08). We noted statistical heterogene-
ity between trials (I² = 98%); therefore, we calculated this com-
parison using a random-effects model (Analysis 1.18).
Serum potassium
Seven trials with a total of 459 participants reported postoper-
ative serum potassium of 4.13 mmol/L in the buffered group
and 4.22 mmol/L in the non-buffered group (Hadimioglu 2008;
Khajavi 2008; Kulla 2008; Nuraei 2010; O’Malley 2005; Song
2015;Wilkes 2001). Data show no important differences between
groups, withMD -0.04mmol/L lower in the buffered group (95%
CI -0.14 to 0.06; I² = 65%; Analysis 1.19).
Serum sodium
Investigators reported this outcome at two time points. Eight trials
with a total of 447 participants reported a serum sodium level
of 137.3 mmol/L in the buffered fluid group and 139.4 mmol/L
in the non-buffered fluid group (Khajavi 2008; Kim 2013; Kulla
2008; Nuraei 2010; Song 2015; Takil 2002; Waters 2001; Wilkes
2001). Data show an important difference between groups, with
MD -2.26 mmol/L higher in the non-buffered group (95% CI
-2.84 to -1.68; I² = 56%; Analysis 1.20).
Two trials with a total of 91 participants reported postoperative
day one serum sodium of 140.6 mmol/L in the buffered fluid
group and 141.8 mmol/L in the non-buffered fluid group (Kulla
2008; Takil 2002). Data show no important differences between
groups, with MD 1.2 mmol/L higher in the non-buffered fluid
group (95% CI -2.55 to 0.12; I² = 0; Analysis 1.20).
Serum lactate
Four trials with a total of 199 participants reported serum lactate
of 2.27 mmol/L in the buffered fluid group and 1.62 mmol/L
in the non-buffered fluid group (Kulla 2008; Song 2015; Waters
2001;Wilkes 2001). Data show no important differences between
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groups, withMD0.52mmol/L higher in the buffered group (95%
CI -0.04 to 1.08). Analysis suggested statistical heterogeneity be-
tween trials (I² = 87%); therefore, we calculated this comparison
using a random-effects model (Analysis 1.21).
Serum calcium
One trial reported postoperative serum calciumof 2.0 ± 0.2mmol/
L in the buffered fluid group and 1.6 ± 0.2 mmol/L in the non-
buffered fluid group (Wilkes 2001). Data show an important dif-
ference between groups. We did not analyse these data and listed
this as an orphan outcome in Table 3.
Hospital length of stay (days)
Five trials with a total of 348 participants reported hospital length
of stay (Base 2011; Gan 1999; O’Malley 2005; Takil 2002;Waters
2001). Reporting was heterogeneous, with data presented as the
median (range) by O’Malley 2005 and as the mean (range) by
Base 2011. We applied the formula used by Hozo to numerically
convert these data to mean (± SD) (Hozo 2005). Data show no
important differences between groups, with MD in hospital stay
of 0.37 (95% CI -0.72 to 1.47; I² = 16%; favouring the non-
buffered groupAnalysis 1.22).
Functional health status and quality of life measures
None of the included trials addressed this outcome.
Cost
None of the included trials addressed this outcome.
D I S C U S S I O N
Summary of main results
Three studies of 267 participants contributing data to the primary
outcome of this review provided evidence suggesting that overall
mortality was low and provided no evidence indicating that choice
of fluids - buffered or non-buffered - influenced mortality (Peto
odds ratio (OR) 1.88, 95% confidence interval (CI) 0.37 to 9.33).
We graded the quality of this evidence as moderate. Analysis of all
secondary outcomes measured by 18 different randomized con-
trolled trials of 1096 participants suggests that intravenous fluids
containing a physiological buffer are a safe alternative to saline-
based fluids for adult patients undergoing surgery. Data show no
differences between groups in terms of renal dysfunction or surro-
gate markers of renal dysfunction (urine output and serum creati-
nine).We rated this evidence as low quality. Results for some of the
other secondary outcomes revealed differences between groups,
including reduced postoperative pH (pH 7.32 vs 7.38, with mean
difference (MD) 0.05 lower in the non-buffered group (95% CI
-0.04 to -0.07)), which suggests that buffered fluids given periop-
eratively are associated with a lesser degree of metabolic acidosis.
We rated this evidence as moderate quality. Four trials with a total
of 267 participants provided evidence on renal insufficiency lead-
ing to the requirement for renal replacement therapy suggesting
that risk of renal insufficiency requiring renal support is lowered
by the use of buffered fluids (4.7% (11/148) vs 9.2% (11/119)),
but we have little confidence that this difference is real (OR 0.82,
95% CI 0.34 to 1.98; I² = 0%). We downgraded the quality of
this evidence to low because of limitations in the design of three
studies that included participants with the confounding effect of
pre-existing organ failure (i.e. participants undergoing renal trans-
plant for renal failure) (Hadimioglu 2008; Kim 2013; O’Malley
2005).
Data show higher postoperative serum chloride levels in the non-
buffered group than in the buffered group (chloride 114.3 mmol/
L vs 107.5 mmol/L, for MD of 6.7 with 95% CI -10.17 to -3.38).
We rated the quality of this evidence as moderate. Higher chloride
concentrations in these fluids might suggest this outcome. Higher
serum chloride is a cause of metabolic acidosis and may explain
our findings of both lower pH and lower partial pressure of arte-
rial carbon dioxide (PaCO2) (secondary to respiratory compensa-
tion for metabolic acidosis) when non-buffered fluids were used
(Stewart 1978).
Overall completeness and applicability of
evidence
This systematic review includes published trials comparing
buffered and non-buffered fluid administration during major elec-
tive surgery in adults only. Such fluids are used in a variety of clini-
cal contexts including trauma resuscitation, burns, and sepsis, and
are given to paediatric patients. Our review did not assess trials
conducted outside the adult perioperative setting, hence we can-
not draw conclusions beyond those applicable to elective surgery
in adults.
Whilst these trials reported many outcomes, very few addressed
our primary outcome of death or major organ system failure -
most studies reported metabolic or symptomatic differences be-
tween groups of patients. Therefore, the numbers reported for our
primary outcome are low, and our analyses may not have detected
differences between patient groups for these outcomes.
Trials within our review included a total of 1096 participants. We
cannot rule out rare adverse effects of buffered or non-buffered
fluid administration for adult surgical patients, but we can con-
clude that both fluids appear equally safe. Some evidence indi-
cates that selection of buffered or non-buffered fluids may have
measurable effects on the composition of plasma in surgical pa-
tients. None of these effects were primary outcomes, and none has
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been shown to directly affect patient outcomes. However, these
metabolic differences may have clinically significant effects that
were not detected by our study. Meta-analysis of high versus low
chloride content of fluid administered to surgical and critical care
patients has indicated a weak but significant association with risk
of acute kidney injury among surgical and critical care patients
(Krajewski 2015). Likewise, a systematic review of near-isotonic
or isotonic crystalloids found evidence to support varying acid-
base status and other physiological outcomes between even rela-
tively similar fluid types (Orbegozo 2014). Results of our review
are compatible with the conclusion that different crystalloid fluids
have different profiles of effects on acid-base status and plasma
electrolyte concentration. However, current available evidence is
insufficient to clearly resolve the question of whether such differ-
ences have clinical applicability by beneficially altering prognosis
for postoperative patients.
Given the lack of evidence on harm and putative benefit for bio-
chemical status, recent guidelines related to perioperative fluid
management have begun to recommend use of balanced salt solu-
tions, such asHartmann’s, in routine clinical practice (GIFTASUP
2011). However, different countries, and indeed different clin-
icians, continue to report conflicting views and practices. The
phenomenon of hyperchloraemic metabolic acidosis and its rela-
tionship to saline-based fluid administration are well understood
among perioperative physicians, and many favour a buffered fluid
preparation. Clinicians who work with other acutely unwell pa-
tient groups may still not be aware of this phenomenon.
Quality of the evidence
A total of 19 publications reported results from 18 randomized
controlled trials enrolling a total of 1096 participants. We judged
the evidence from these trials to be of moderate to low quality by
using GRADEproGDT software (GRADEproGDT 2015). Data
for several outcomes show considerable heterogeneity between
study populations. Differences in the characteristics of patients
undergoing surgery ranged fromAmerican Society of Anesthesiol-
ogists (ASA) I and II status in patients who were relatively well, to
ASA III or greater status among those with end-stage organ failure.
Such a broad range of patients would suggest a similarly broad
range of expected outcomes, and thus reduced generalizability of
observed outcomes to the surgical population as a whole. For ex-
ample, the observation that choice of fluid may be associated with
differences in the numbers of patients with end-stage renal insuffi-
ciency who progress to postoperative organ failure may be true of
that specific population of patients but may not be true for a pop-
ulation with normal renal function. Therefore, one must exercise
caution when interpreting these results. For this reason, we down-
graded the quality of evidence for this specific outcome by two
levels to low. Similarly, trials showmajor differences in the types of
surgery under investigation. Some included trials examined very
minor surgery in otherwise fit and healthy patients (Chin 2006).
Others analysed outcomes after major surgery in high-risk patient
groups (Waters 2001;Wilkes 2001), and some focused only on re-
nal transplant surgery. This clinical heterogeneity among surgical
procedures exacerbates the difficulty encountered in interpreting
trial results and in ascertaining their applicability to the general
population.
Most included trials were of high methodological quality (see
Figure 3), although some did not specify blinding methods used
and one was explicitly unblinded. Figure 2 illustrates that few
studies demonstrated high risk of bias. This same figure reveals
that many studies had unclear risk of bias. It remains unclear to
the authors of this review whether these findings were simply a
result of poor reporting of methods, or were reflective of poor trial
design.
Data for some outcomes were highly skewed. Whilst we analysed
these data using the most appropriate method that we could iden-
tify, one must regard review conclusions with caution. For exam-
ple, patients receiving non-buffered fluids were given an increased
volume of platelets compared with those in the buffered fluid
group. These data were highly skewed (standard deviation divided
by the mean was < 1). Confidence intervals for this pooled effect
were large for logged data, indicating that the pooled estimate is
not very precise. More data are required to determine whether dif-
ferences between groups in the quantity of platelets transfused are
indeed important.
We also found differences in various estimates of coagulation func-
tion, such as end of surgery levels of von Willebrand factor and
Factor VIII. Two studies reported these outcomes upon comparing
buffered colloids versus non-buffered colloids (Gan 1999; Kulla
2008). These results should be interpreted with caution, as we
analysed only two studies with few participants.
This review identified small numbers of patients and low num-
bers of events across outcomes of interest, including the primary
outcome of mortality. Awareness of this, along with unclear risk
of bias, perhaps reflective of poor reporting, should lead us to in-
terpret review results with caution. Larger randomized controlled
trials are needed to assess the clinical implications of our findings.
Potential biases in the review process
We tookmeasures to reduce bias throughout this systematic review
process, and we adhered to guidance provided in the Cochrane
Handbook for Systematic Reviews of interventions (Higgins 2011).
Multiple review authors worked independently to assess risk of
bias and study eligibility, and to extract data from studies included
in this review.
Two review authors (PO and SB) worked independently to assess
eligibility of studies against inclusion criteria and to extract data
from the 19 primary publications. We consulted a third review
author (EB) when we sought to resolve disagreements. Two review
authors independently assessed risk of bias and ranked the quality
of studies.
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Trials identified for inclusion in this review were heterogeneous
with regards to groups studied, reported outcomes, and time points
of assessment. This led to us report many outcomes based on small
patient groups at different time points. Many studies included
co-interventions that were not ubiquitous across all studies. For
example, some studies administered different types of fluids such as
colloids and blood alongside trial fluids. In addition, heterogeneity
within some analyses was pronounced (this is particularly true
of Analysis 1.19), and this may have weakened the robustness of
review results.
Some trial data did not contribute to our analyses because they
were reported in weight-based units rather than in absolute
amounts. We attempted to contact trial authors to obtain indi-
vidual participant data, but we were not always successful in these
attempts.
Although we made all efforts possible to retrieve relevant trials, we
included only data that were published in peer-reviewed journals.
Other high-quality data may remain unpublished, or may be pub-
lished in the grey literature. Therefore, our analysis is at risk of pub-
lication bias. Additionally, we discovered only two trials that were
published in a language other than English - one bi-lingually in
German andEnglish, the other in Farsi (Kulla 2008,Nuraei 2010).
We might have failed to identify other trials. We reran the search
inMay 2017 and found one study of interest (Pfortmueller 2017).
We added this study to a list of Studies awaiting classification and
will incorporate it into formal review findings during the review
update.
Agreements and disagreements with other
studies or reviews
To the best of our knowledge, no other systematic reviews have
compared effects of buffered versus non-buffered fluid adminis-
tration in any patient group.
The UK clinical guideline on intravenous fluid therapy (
GIFTASUP) states that owing to the relationship between non-
buffered fluids and hyperchloraemic metabolic acidosis, these flu-
ids should be avoided in favour of buffered fluids, except in special
circumstances. The data from our review support this statement.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Perioperative fluid administration includes an array of different
fluid types, including buffered and non-buffered fluids. Our sys-
tematic review identifiedmoderate-quality evidence to support the
safety of buffered fluids in terms of their low risk of precipitating
electrolyte disturbance. In particular, evidence in our review shows
that perioperative buffered fluid resuscitation is associated with
hyperchloraemicmetabolic acidosis in a reduced proportion of pa-
tients when comparedwith non-buffered fluid resuscitation. Some
patients, including those with hypernatraemic acidaemia, are at
increased risk of postoperative metabolic derangement. Buffered
fluids are appropriate for fluid replacement during surgery and
should be considered especially for patients with, or at risk of,
metabolic derangement.
However, our review has not presented evidence to support a dif-
ference in our primary outcome (i.e. mortality) between buffered
and non-buffered fluids. Likewise, although buffered fluids are
demonstrably safe when compared with non-buffered fluids, the
ultimate choice regarding administration of fluid to meet individ-
ual patient requirements remains at the discretion of the clinician.
Implications for research
These data were derived from studies of variable quality and re-
main underpowered to detect any morbidity or mortality arising
from selection of buffered or non-buffered fluids for administra-
tion during the perioperative period. One of the key limitations
of these studies, which has consequences for the generalizability
of the findings of this review, was the heterogeneity of protocols
for fluid administration, including wide variation in volumes of
fluid administered across studies and in targets used to drive fluid
administration. Additional studies are needed, including specifi-
cally a large, adequately powered and appropriately blinded ran-
domized controlled trial of sufficient power to detect differences
in clinical outcomes arising from the physician’s choice of fluid.
Future trials should seek to identify trends in meaningful patient-
centred outcomes such as mortality, quality of recovery, length of
hospital stay, and organ dysfunction, and in quality of life mea-
sures such as postoperative pain. One large study of saline versus
Ringer’s lactate that assessed major postoperative complications as
its primary outcome measure is currently ongoing and is expected
to be completed in 2022.
Our review examined effects of buffered and non-buffered fluids
on adult surgical patients. Several other patient groups, for exam-
ple, surgical and medically unstable paediatric patients and crit-
ically ill adult patients in the intensive care unit, also are treated
with large volumes of intravenous fluid. Clinical trials are com-
paring use of buffered and non-buffered fluids in these patient
populations. A systematic review of these data may reveal findings
consistent with the findings presented in our review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Base 2011
Methods Design: randomized controlled study
Withdrawals: no withdrawals
Setting: 2 European cardiac surgery hospitals
Sample size: 81 cardiac surgical patients
Participants Age (mean): 64.6/67.9 years
Gender (M/F): 62/19
ASA grade: not reported
Surgery type: CABG/valve surgery/CABG + valve surgery
Surgery duration (mean): 4.1/3.8 hours
Anaesthesia type: general
Interventions Interventionn = 43
Buffered arm-Balanced 6%HES 130/0.4 (Volulyte) for intraoperative and postoperative
fluid administration
Control n = 38
Non-Buffered arm - 6%HES 130/0.4 in saline for intraoperative and postoperative fluid
administration
Co-interventions: none
Outcomes Acid-base status, serum biochemistry up to 24 hours postoperatively. Duration of ICU
stay, duration of hospital stay, and mortality all measured up to 30 days postoperatively
Notes Funding source: not disclosed
Declarations of interest: 1 study author was employed by Fresenius Kabi, which manu-
factured the intervention being studied (Voluven)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed using
SAS” and “patients were randomized to
treatment groups per study centre in blocks
of 6”
Allocation concealment (selection bias) Low risk As above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial was blinded to participants and inves-
tigators.
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Base 2011 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specified whether outcome assessment
was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis - nowithdrawals
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Unclear risk One study author is employed by the man-
ufacturer of the fluids compared in the
study
Chin 2006
Methods Design: randomized controlled study
Withdrawals: 10 participants excluded for protocol violations (from total 60 participants
recruited)
Setting: single hospital in Singapore
Sample size: 50; 3 arms to the trial
One arm consisted of participants who received a fluid formulation that was not relevant
to this review (dextrose 5% in 0.9% saline). Details for this arm of the study are not
extracted here
Participants Age (mean): 50/35 years
Gender (M/F): 21/11
ASA grade: I or II
Surgery type: elective surgery that was not expected to enter into amajor body cavity, or to
require intravenous fluid volume in excess of 500 mL in the first 2 hours of perioperative
care. Covered orthopaedic, ENT, breast, minor general surgery
Surgery duration (mean): 1.5/1.2 hours
Anaesthesia type: general
Interventions Intervention n = 16
Buffered arm - 500 mL lactated Ringer’s solution administered over 45 to 60 minutes
Control n = 16
Non-buffered arm - 500 mL 0.9% normal saline administered over 45 to 60 minutes
Co-interventions: none
Outcomes Serum glucose and electrolytes, measured up to 1 hour postoperatively
Notes This trial was performed on participants undergoing only minor surgery, who received
only a small amount of intravenous fluid. Study was designed to investigate effects on
serum glucose of infusion fluids containing or not containing a small amount of glucose.
It was not designed as a trial to compare effects of buffered vs non-buffered fluids
Datawere reported asmeans (95%CIs) andwere converted intomeans (SDs) for analysis
Funding source: not disclosed
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Chin 2006 (Continued)
Declarations of interest: not disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomized via a com-
puter-generated
random number table and sealed opaque
envelopes.
Allocation concealment (selection bias) Low risk See above.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial was blinded to participants and inves-
tigators (personal communication)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
High risk A high proportion of participants (20%)
dropped out owing to administration of
non-protocol intravenous fluids
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk No evidence of other potential bias
Gan 1999
Methods Design: randomized controlled study
Withdrawals: 3 participants owing to protocol violations
Setting: 2 centres (USA)
Sample size: 120
Participants Age (mean): 58/57
Gender (M/F): 69/61
ASA grade: I to III
Surgery type: major elective surgery, which covered orthopaedic, general, gynaecological,
and urological needs
Surgery duration (mean): 5.3/5.2 hours
Anaesthesia type: general
Interventions Intervention n = 60
Buffered arm - Hextend administered via a hypovolaemia algorithm to ensure adequate
volume during the operation
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Gan 1999 (Continued)
Control n = 60
Non-buffered arm - Hespan administered via a hypovolaemia algorithm to ensure ade-
quate volume during the operation
Co-interventions: Each arm was given a maintenance dose of lactated Ringer’s solution
(a buffered fluid)
Outcomes Urine output, EBL, intraoperative transfusion, death, length of postoperative stay, re-
quirement for calcium measured and recorded during hospital stay
Notes Funding source: BioTime biotechnology company
Declarations of interest: disclosure of funding source
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequences were generated via a computer
programme.
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinding of participants, trial conductors
and assessors
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Three participants did not receive study so-
lution.
Selective reporting (reporting bias) Low risk No evidence of selection bias. All pro-
posed outcome measures adequately re-
ported. All exclusions for protocol viola-
tions. No cross-overs
Other bias Unclear risk Analysis was done on an intention-to-treat
basis. Study was funded in part by BioTime
Inc., which manufactures Hextend
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Hadimioglu 2008
Methods Design: randomized double-blinded controlled trial
Withdrawals: Not reported
Setting: not specified whether this is a single-centre or multi-centre study
Sample size: 90
3 arms to the study, each with 30 participants
Participants Age (mean): normal saline 44.4, lactated Ringer’s 48.3, Plasmalyte 46.3 years
Gender (M/F): not specified
ASA grade: III to IV with end-stage renal failure
Surgery type: living-related kidney transplants
Surgery duration (mean): normal saline 2 hours, lactated Ringer’s 2 hours, Plasmalyte 2
hours
Anaesthesia type: general
Interventions Intervention 1 n = 30
Buffered arm - Lactated Ringer’s
Intervention 2 n = 30
Buffered arm - Plasmalyte 148
Control n = 30
Non-buffered arm- Normal saline
Co-interventions: all fluids administered at 20 to 30 mL/kg/h to maintain CVP at 12
to 15 mmHg
The 2 buffered arms (lactated Ringer’s solution and Plasmalyte 148) were numerically
combined, so that the buffered fluid arm included 60 participants and the non-buffered
fluid arm included 30 participants
Outcomes Urine output, pH, base excess, lactate, bicarbonate, potassium,CO2 , chloride, creatinine,
creatinine clearance, chloride, requirement for dialysis measured daily until the third
postoperative day and then once more on the seventh postoperative day
Notes Funding source: not disclosed
Declarations of interest: none
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer randomization programme
was used for participant group assignments
Allocation concealment (selection bias) Unclear risk No information forthcoming
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded - study solutions prepared
in
unlabeled bags by the hospital pharmacy.
Participants and clinicians blinded to group
assignments
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Hadimioglu 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No participants lost to follow-up
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcomemeasures adequately reported.No
participants lost to follow-up
Other bias Low risk No further data available
Heidari 2011
Methods Design: randomized double-blinded controlled trial
Withdrawals: none
Setting: single centre in the Middle East
Sample size: 90; 3 groups within the trial
Participants Age (mean): 43.6/40.9 years
Gender (M/F): 28/32
ASA grade: I to II
Surgery type: elective lower abdominal surgery
Surgery duration (mean): 1.3/1.5 hours
Anaesthesia type: general
One arm consisted of participants who received a fluid formulation that was not relevant
to this review. Details for this arm of the study are not extracted here
Interventions Intervention n = 30
Buffered arm - Ringer’s lactate 15 mL/kg administered 30 minutes preoperatively
Control n = 30
Non-buffered arm - normal saline 15 mL/kg administered 30 minutes preoperatively
Co-interventions: none
Outcomes Postoperative nausea using VAS and incidence of postoperative vomiting at 6, 12, and
24 hours postoperatively
Notes Funding source: not disclosed
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocated randomly according to random
number table
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Heidari 2011 (Continued)
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as ’double-blinded’ but blinding
methods not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Reported as ’double-blinded’ but blinding
methods not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No participants lost to follow-up
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Unclear risk Type of surgery not described in detail
Khajavi 2008
Methods Design: randomized double-blinded controlled trial
Withdrawals: none
Setting: single centre in the Middle East
Sample size: 52
Participants Age (mean): 40/37 years
Gender (M/F): not described in detail, but groups described as sex-matched
ASA grade: not described
Surgery type: elective renal transplantation surgery
Surgery duration (mean): not described
Anaesthesia type: general
Interventions Intervention n = 26
Buffered arm - Ringer’s lactate 60 mL/kg titrated to a CVP of 10 to 15 mmHg
Control n = 26
Non-buffered arm - normal saline 60 mL/kg titrated to a CVP of 10 to 15 mmHg
Co-interventions: none
Outcomes Electrolytes, pH, blood loss, graft failure, urine output
Blood samples measured at the start of surgery, at 1 hour, and at end of surgery. Urine
output measured first 4 hours postoperatively
Notes Funding source: not disclosed
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
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Khajavi 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Sealed envelopes
Allocation concealment (selection bias) Low risk Fluids covered in opaque tape
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants lost to follow-up
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk No other obvious bias
Kim 2013
Methods Design: randomized double-blinded controlled trial
Withdrawals: none
Setting: single centre in Korea
Sample size: 60
Participants Age (mean): 48/44 years
Gender (M/F): 38/22
ASA grade: not described
Surgery type: elective renal transplantation surgery
Surgery duration (mean): 4.4/4.3 hours
Anaesthesia type: general
Interventions Intervention n = 30
Buffered arm - Ringer’s lactate infusion to maintain CVP of 12 to 15 mmHg
Control n = 30
Non-buffered arm - normal saline infusion to maintain CVP of 12 to 15 mmHg
Co-interventions: none
Outcomes pH, base excess, strong ion difference, urine output, postoperative creatinine, graft failure
requiring dialysis up to day 7 postoperatively
Notes Funding source: not disclosed
Declarations of interest: none disclosed
Risk of bias
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Kim 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized according to random number
sequence
Allocation concealment (selection bias) Low risk Solutions in unlabelled bags
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants lost to follow-up
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk All participant data reported
Kulla 2008
Methods Design: randomized double-blinded controlled trial
Withdrawals: 1
Setting: single centre in Germany
Sample size: 62
Participants Age (mean): adult
Gender (M/F): not described
ASA grade: 2 to 3
Surgery type: elective major abdominal surgery
Surgery duration: Not reported
Anaesthesia type: general
Anticipated surgery longer than 90 minutes with more than 1.5 L fluid requirement.
Postoperative intensive care required
Interventions Intervention n = 29
Buffered arm - buffered HES as colloid and acetated Ringer’s solution
Control n = 33
Non-buffered arm - HES in saline-based solution as colloid plus a non-balanced crys-
talloid
Co-interventions: none
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Kulla 2008 (Continued)
Outcomes Endpoints taken preoperatively, during surgery, at end of surgery, 6 hours postoperatively,
and at POD1
blood loss, urine output, creatinine, lactate, sodium, chloride, PaO2, PaCO2, pH, base
excess, thromboplastin time “quick”, partial thromboplastin time, antithrombin III,
Factor VIII, von Willebrand factor, ristocetin cofactor
Notes Very heterogeneous group of surgical procedures, including 1 each of oesophagectomy,
gastrectomy, prostatectomy, nephrectomy, and colonic surgery
Funding source: not disclosed
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomized - method unclear
Allocation concealment (selection bias) Unclear risk Unclear
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant lost to follow-up
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Unclear risk Of 62 participants enrolled, 1 was lost
to follow-up, as the operation was not
performed as expected. No further infor-
mation is available. One author of this
study was employed by Serumwerk Bern-
burg AG, which manufactures hydrox-
yethyl starch (HES)
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Martin 2002
Methods Design: randomized controlled trial
Withdrawals: none
Setting: single centre (USA)
Sample size: 90
Participants Age (mean): 6% Hetastarch in normal saline 58, 6% Hetastarch in balanced saline 59,
lactated Ringer’s solution 58
Gender (M/F): not described
ASA grade: I to III
Surgery type: major elective non-cardiac surgery with anticipated blood loss of 500 mL
Surgery duration (mean): not described
Anaesthesia type: general
Interventions Three arms, only 2 of which are included (60 participants)
30 patients were enrolled into the buffered (Hextend) arm; and 30 into the non-buffered
arm (Hespan). Trial fluids were given according to a protocol, to ensure adequate volume
during the operation. In addition, each arm was given a maintenance dose of lactated
Ringer’s solution (a buffered fluid)
Outcomes TEG data measured before induction, at end of surgical procedure, and 24 hours post-
operatively
Notes These are the same participant data as in Moretti 2003, but different outcomes are
reported.
Funding source: supported in part by a grant from BioTime, Inc
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded to participants, trial conductors
and assessors
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded to participants, trial conductors
and assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant in each group fell out -
1 did not need study fluid, the other had
surgery rescheduled
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Martin 2002 (Continued)
Selective reporting (reporting bias) Low risk No evidence of selection bias. All pro-
posed outcome measures adequately re-
ported. Analysis completed on an inten-
tion-to-treat basis
Other bias Unclear risk Study was funded in part by BioTime Inc.
, which manufactures Hextend
McFarlane 1994
Methods Design: randomized controlled trial
Withdrawals: none
Setting: single centre (UK)
Sample size: 30
Participants Age (mean): 57/54 years
Gender (M/F): not described
ASA grade: I or II
Surgery type: major elective hepatobiliary or pancreatic surgery
Surgery duration (mean): 3.3/3.7 hours
Anaesthesia type: general
Interventions Intervention n = 15
Buffered arm - Plasmalyte 148 infusion 15 mL/kg/h
Control n = 30
Non-buffered arm - normal saline infusion 15 mL/kg/h
Rate adjusted in response to clinical state, but not according to a clinical protocol
Co-interventions: all fluids warmed
Outcomes Blood loss (mL/kg) mean and SD, chloride, bicarbonate, base excess, PaCO2, lactate up
to 24 hours postoperatively
Notes Funding source: not disclosed
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization method not clear
Allocation concealment (selection bias) High risk No evidence of allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No evidence of blinding
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McFarlane 1994 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No evidence of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data complete
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk No other information forthcoming
Moretti 2003
Methods Design: randomized controlled trial
Withdrawals: 2
Setting: single centre USA
Sample size: 90
Participants Age (mean): buffered (Hextend) arm 59, non-buffered arm (Hespan) 58
Gender (M/F): not described
ASA grade: I to III
Surgery type: major elective general, gynaecological, orthopaedic, or urological with
anticipated blood loss > 500 mL
Surgery duration (mean): 4.6/4.8 hours
Anaesthesia type: general
Interventions Three arms, only 2 of which are included
30 participants were enrolled into the buffered (Hextend) arm, and 30 into the non-
buffered arm (Hespan). Trial fluids were given according to a protocol, to ensure adequate
volume during the operation. In addition, each arm was given a maintenance dose of
lactated Ringer’s solution (a buffered fluid)
Outcomes Postoperative nausea and vomiting, oedema up to 24 hours after surgery
Notes These are the same participant data as in Martin 2002, but different outcomes are
reported.
Funding source: supported in part by a grant from BioTime, Inc
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequence
Allocation concealment (selection bias) Low risk Sealed envelopes
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Moretti 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded to participants, trial conductors
and assessors
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Independent research personnel unaware of
participant’s collected randomization data
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 participant from each group did not pro-
ceed with fluid allocation
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Unclear risk One participant in each group fell out -
1 did not need study fluid, and the other
had surgery rescheduled. Analysis was com-
pleted on an intention-to-treat basis. Study
was funded in part by BioTime Inc., which
manufactures Hextend
Nuraei 2010
Methods Design: randomized controlled trial
Withdrawals: none
Setting: single centre, Iran
Sample size: 108
Participants Age (mean): 38/39 years
Gender (M/F): 68/40
ASAgrade: “I and II” -NB: All participants had end-stage renal disease andwere awaiting
transplant
Surgery type: renal transplant surgery
Surgery duration (mean): 2.1/2.0 hours
Anaesthesia type: general
Interventions Intervention n = 54
Buffered arm - Ringer’s lactate
Control n = 54
Non-buffered arm - normal saline
Protocol for fluid administration not reported
Co-interventions: none
Outcomes Renal function, acid-base status up to 24 hours after surgery
Notes Funding source: not disclosed
Declarations of interest: none disclosed
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Nuraei 2010 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized double-blinded trial
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All outcomes adequately reported
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk No other obvious bias
O’Malley 2005
Methods Design: prospective randomized double-blind controlled study
Withdrawals: 3
Setting: single centre, USA
Sample size: 54
Participants Age (mean): 44/44 years
Gender (M/F): 32/19
ASA grade: > III
Surgery type: renal transplantation
Surgery duration (mean): 5.6/5.6 hours
Anaesthesia type: general
A total of 54 participants with end-stage renal failure undergoing kidney transplantation
were recruited. Of these, 3 were excluded owing to high preoperative potassium (total
analysed 51)
Interventions Intervention n = 25
Buffered arm - Ringer’s lactate
Control n = 26
Non-buffered arm - normal saline
Fluids titrated to routine clinical endpoints
Co-interventions: dopamine infusion 2 mcg/kg/min
42Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical
procedures (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
O’Malley 2005 (Continued)
Outcomes Serum potassium, pH, serum creatinine up to 1 week, postoperative urine output, cre-
atinine clearance, requirement for dialysis, blood loss, transfusion requirements, length
of stay in hospital
Notes Trial was stopped early when severe hyperkalaemia was noted in some participants in the
control arm
Funding source: not disclosed
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Closed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind” - method unclear
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 participants excluded preoperatively on
the basis of predetermined exclusion crite-
ria
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk No evidence of other potential bias
Scheingraber 1999
Methods Design: prospective randomized double-blind controlled study
Withdrawals: none
Setting: single centre, USA
Sample size: 24
Participants Age (mean): 53/46 years
Gender (M/F): all female
ASA grade: I to II
Surgery type: elective gynaecological surgery
Surgery duration (mean): 2.3/2.3 hours
Anaesthesia type: general
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Scheingraber 1999 (Continued)
Interventions Intervention n = 12
Buffered arm - Ringer’s lactate
Control n = 12
Non-buffered arm - normal saline
30 mL/kg/h
Co-interventions: supplemental intravenous potassium administered according to intra-
operative serum potassium levels
During the study, no participants received colloids, plasma products, or blood transfu-
sions
Outcomes Estimated intraoperative blood loss, urine output, pH, carbon dioxide, base excess,
lactate, chloride, sodium
Notes Funding source: not disclosed
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomization details not available
Allocation concealment (selection bias) Unclear risk No details available
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Published data state that double-blinding
took place. No other details are available
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No participants lost to follow-up
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk No other information forthcoming
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Song 2015
Methods Design: randomized double-blinded study
Withdrawals: 0
Setting: single centre, Korea
Sample size: 50
Participants Age (mean): 60/63
Gender (M/F): 17/33
ASA grade: I to II
Surgery type: elective lumbar spinal surgery
Surgery duration (mean): 4.9/4.85 hours
Anaesthesia type: general
Interventions Intervention n = 25
Buffered arm - Plasmalyte
Control n = 25
Non-buffered arm - normal saline
6 mL/kg/h increased at discretion of anaesthetist
Co-interventions: If blood loss > 500 mL, participants were given a colloid (6% HES in
saline). If haematocrit decreased to < 24%, blood was given. No significant differences
between groups in volumes of blood or colloid administered
Outcomes Rotational thromboelastometry (ROTEM) at end of surgery. Intraoperative blood loss,
pH, BE, bicarbonate. Postoperative electrolytes at 12 hours
Urea and creatinine at 24 hours
Notes Funding source: supported by a university grant
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number se-
quence
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Anaesthetists performing ROTEM were
blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No participants were lost to follow-up.
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Song 2015 (Continued)
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk No other apparent bias
Takil 2002
Methods Design: randomized controlled study
Withdrawals: 0
Setting: single centre, Turkey
Sample size: 30
Participants Age (mean): 37/45 years
Gender (M/F): not reported
ASA grade: I to II
Surgery type: elective major spinal surgery
Surgery duration (mean): 4.9/4.9 hours
Anaesthesia type: general
Interventions Intervention n = 15
Buffered arm - Ringer’s lactate
Control n = 15
Non-buffered arm - normal saline
20 mL/kg/h
Co-interventions: If blood loss > 500 mL, participants were given a colloid (Gelofusine)
. If blood loss > 20%, blood was given
Outcomes Sodium, chloride, bicarbonate, base deficit, pH, blood transfusion, blood loss, urine
output, PaCO2 up to 12 hours after surgery. Length of intensive care unit and hospital
stay recorded
Time points were first, second, fourth, sixth, and twelfth hours postoperatively
Notes Funding source: not disclosed
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Trial was randomized, but no details about
randomization are available
Allocation concealment (selection bias) Low risk Sealed envelopes were used.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not mentioned at all in the
manuscript.
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Takil 2002 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not disclosed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk No other information available
Walsh 1983
Methods Design: randomized controlled study
Withdrawals: 0
Setting: single centre, UK
Sample size: 21
Participants 3 arms included in the trial, with 7 participants in each. Arms were given lactated Ringer’s
solution, 5% dextrose, and normal saline. Only 2 arms were included for analysis (N =
14)
Age (mean): Hartmann’s 55/normal saline 50 years
Gender (M/F): not reported
ASA grade: not reported
Surgery type: elective cholecystectomy
Surgery duration (mean): not reported
Anaesthesia type: general
Interventions Intervention n = 7
Buffered arm - Hartmann’s solution
Control n = 7
Non-buffered arm - normal saline
6 mL/kg/h
Co-interventions: none
Outcomes Estimated blood loss measured intraoperatively
Notes Funding source: not disclosed
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Methods of randomization unclear
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Walsh 1983 (Continued)
Allocation concealment (selection bias) High risk Allocation concealment not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Blinding not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk No other information given
Waters 2001
Methods Design: randomized controlled study
Withdrawals: 0
Setting: single centre, USA
Sample size: 66
Participants Age (mean): 70/70 years
Gender (M/F): not reported
ASA grade: average III.1
Surgery type: open abdominal aortic aneurysm surgery
Surgery duration (mean): not reported
Anaesthesia type: general + thoracic epidural
Interventions Intervention n = 33
Buffered arm - lactated Ringer’s
Control n = 33
Non-buffered arm - normal saline
Fluids administered to maintain CVP to within 10% of baseline. Colloid administration
restricted to period of rapid blood loss
Co-interventions: Protocol allowed sodium bicarbonate to be given to participants if
their metabolic acidosis was significant. Participants were given human albumin solution
in addition to study fluid at the discretion of the anaesthetic team. All cell-salvaged blood
was washed in normal saline
Non-buffered arm received an average of 1500 mL more fluid intraoperatively
Outcomes Urine output, creatinine, need for renal replacement therapy, EBL, transfusion require-
ments, base deficit, chloride, death, length of postoperative stay
Variables were measured at start of surgery, on admission to ICU, and every 24 hours
until normalization of measured variable
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Waters 2001 (Continued)
Notes Funding source: supported in part by a grant fromCentre forHealthOutcomes Research
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized by a computerized random
number generator
Allocation concealment (selection bias) Low risk Sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded: labels of solutions covered
from participants, trial conductors and as-
sessors
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No withdrawals
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Low risk No other information available
Wilkes 2001
Methods Design: prospective randomized double-blinded
Withdrawals: 5
Setting: 2 centres, UK
Sample size: 47
Participants Age (mean): 71.6/73.1 years
Gender (M/F): 23/24
ASA grade: average I to III
Surgery type: major non-cardiac surgery
Surgery duration (mean): 3.3/3.1 hours
Anaesthesia type: general
Interventions Intervention n = 23
Buffered arm - Hartmann’s and 6% Hetastarch
Control n = 24
Non-buffered arm - normal saline and 6% Hetastarch
500 mL of colloid at induction as a bolus followed by 7 mL/kg/h of crystalloid as an
infusion according to a predefined algorithmic protocol
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Wilkes 2001 (Continued)
Co-interventions: 6% Hetastarch
Outcomes Chloride, sodium, RBCs transfused, platelets transfused, FFP transfused, urine output,
base excess, pH, PaCO2, bicarbonate measured postoperatively
Notes Trial was stopped early after 1 participant experienced adverse effects that may have been
caused by the study fluid
Funding source: supported in part by a grant fromAbbott Laboratories and fromBioTime
Inc
Declarations of interest: none disclosed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization and stratification were in-
stituted with the use of permuted blocks
with a size of 4
Allocation concealment (selection bias) Low risk All clinicians involved in the care of partic-
ipants were blinded to group allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded - participants, trial con-
ductors and assessors
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blinded - participants, trial con-
ductors and assessors
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 5 withdrawals. Study was stopped early af-
ter adverse effects possibly linked to study
fluid
Selective reporting (reporting bias) Low risk No evidence of selection bias. All proposed
outcome measures adequately reported
Other bias Unclear risk Study was funded in part by BioTime Inc.
, which manufactures Hextend
ASA: American Society of Anesthesiologists; BE:base excess; CABG: coronary artery bypass graft; CI:chloride; CO2: carbon dioxide;
CVP: central venous pressure; EBL: estimated blood loss; ENT: ear, nose, and throat; FFP: fresh frozen plasma; HES: hydroxyethyl
starch; Hg: mercury; ICU: intensive care unit; kg: kilogram; L: litre; min: minutes; mL: millilitres; mm: millimetres; NS: normal
saline; PaCO2: partial pressure of arterial carbon dioxide; PaO2: partial pressure of arterial oxygen; POD1: postoperative day 1;
RBCs: red blood cells; ROTEM: Rotational Thromboelastometry (trade name); SAS: Statistical Analysis Software (trade name);
SD: standard deviation; TEG: thromboelastography; VAS:visual analogue scale; vs: versus.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bennett-Guerrero 2001 Information available in abstract form only. No further information available
Bick 1995 Not a randomized controlled trial
Boldt 1993 No buffered fluid group
Boldt 2002a Study retracted
Boldt 2002b Study retracted
Boldt 2007 Study retracted
Boldt 2009 Study retracted
Boldt 2010 Study retracted
Campbell 1990 Non-balanced group received a non-isotonic solution.
Choi 2010 Difference between 3 groups was not just buffered vs non-buffered (1 group received highmolecular weight
HES, whilst the other received low molecular weight HES)
Evans 2003 Different fluid categories. No buffered group
Javnrin 1980 No buffered fluid group
Kaplan 2001 ICU patients - not perioperative. Retrospective, not controlled
Krebbel 2014 Balanced group received crystalloid and colloid.
Lowery 1967 Non-randomized study
Protsenko 2009 Sepsis patients
Reid 2003 Volunteer study
Roche 2006 In vitro study
Ruttman 1996 In vitro study. No buffered group
Walker 2001 Retrospective, case control study
Williams 1999 Volunteer study
Young 2015 ICU patients - not perioperative
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HES: hydroxyethyl starch; ICU: intensive care unit; vs: versus.
Characteristics of studies awaiting assessment [ordered by study ID]
Pfortmueller 2017
Methods Randomized controlled trial of acetate-buffered crystalloid infusion vs infusion of 0.9% saline and haemodynamic
stability in patients undergoing renal transplantation
Participants 150 participants
Interventions 76 participants received 0.9% saline perioperatively.
74 participants received an acetate-buffered balanced crystalloid (Elomel Isoton)
Outcomes Cumulative vasopressor dose (µg/kg/min)
Use of catecholamines
Mean minimum arterial blood pressure
Peak chloride levels
Serum sodium levels
Notes
Characteristics of ongoing studies [ordered by study ID]
NCT02565420
Trial name or title Saline versus lactated Ringer’s solution: the SOLAR fluid trial
Methods Randomized controlled trial of lactated Ringer’s solution vs normal saline for intraoperative fluid management
Participants Estimated enrolment: 8548 participants
Interventions Active comparator: lactated Ringer’s solution
During perioperative period of colorectal, orthopaedic, or similar surgery, participant will receive an inter-
vention of lactated Ringer’s solution fluids
Placebo comparator: normal saline
During perioperative period of colorectal, orthopaedic, or similar surgery, participant will receive an inter-
vention of normal saline solution
Outcomes Primary: major postoperative complications
Secondary: economic evaluation
Starting date September 2015
Contact information Roberta Johnson, 216-444-9950; johnsor13@ccf.org
Notes ClinicalTrials.gov identifier: NCT02565420
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D A T A A N D A N A L Y S E S
Comparison 1. Buffered versus non-buffered
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (all time frames
reported)
3 267 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.85 [0.37, 9.33]
2 Organ system failure - renal
insufficiency requiring support
4 267 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.34, 1.98]
3 Urine output (mL) 8 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Intraoperative urine
output (mL)
8 459 Mean Difference (IV, Random, 95% CI) 6.10 [-128.41, 140.
61]
3.2 Intraoperative urine
output (mL) - sensitivity
analysis after exclusion of
O’Malley 2005
6 348 Mean Difference (IV, Random, 95% CI) 9.93 [-147.01, 166.
87]
3.3 Renal transplant patients 2 111 Mean Difference (IV, Random, 95% CI) 58.26 [-446.70, 563.
21]
4 Creatinine change (µmol/L) 2 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Postoperative creatinine
change (µmol/L)
2 113 Mean Difference (IV, Random, 95% CI) -6.96 [-27.42, 13.
50]
4.2 Postoperative day 1
creatinine change (µmol/L)
2 113 Mean Difference (IV, Random, 95% CI) 4.94 [-5.91, 15.78]
5 Postoperative creatinine
(µmol/L)
7 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Postoperative creatinine 3 235 Mean Difference (IV, Fixed, 95% CI) -1.31 [-9.30, 6.68]
5.2 Postoperative day 1
creatinine
3 211 Mean Difference (IV, Fixed, 95% CI) -6.26 [-21.17, 8.64]
5.3 Postoperative day 3
creatinine
4 301 Mean Difference (IV, Fixed, 95% CI) -0.47 [-30.12, 29.
19]
5.4 Postoperative week 1
creatinine
4 309 Mean Difference (IV, Fixed, 95% CI) -5.36 [-25.29, 14.
56]
6 Postoperative creatinine
clearance (mL/min)
3 222 Mean Difference (IV, Fixed, 95% CI) 12.61 [-2.31, 27.54]
7 PaCO2 (mmHg) 7 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 Postoperative PaCO2 7 446 Mean Difference (IV, Fixed, 95% CI) 1.05 [0.15, 1.94]
7.2 Postoperative day 1
PaCO2
2 91 Mean Difference (IV, Fixed, 95% CI) 3.33 [2.03, 4.64]
8 Postoperative nausea and
vomiting
3 168 Odds Ratio (M-H, Fixed, 95% CI) 0.66 [0.34, 1.30]
9 Intraoperative blood loss (mL) 11 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Intraoperative blood loss <
1000 mL
5 202 Mean Difference (IV, Fixed, 95% CI) 5.90 [-45.18, 56.99]
9.2 Intraoperative blood loss
≥ 1000 mL
6 374 Mean Difference (IV, Fixed, 95% CI) -173.07 [-438.83,
92.68]
10 Intraoperative red cell
transfusion
4 152 Mean Difference (IV, Fixed, 95% CI) -29.10 [-117.03, 58.
84]
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11 Intraoperative transfusion -
other products (log values)
4 Mean Difference (Fixed, 95% CI) Subtotals only
11.1 Platelet transfusion
(Higgins 3)
4 Mean Difference (Fixed, 95% CI) 1.23 [0.22, 2.25]
11.2 Fresh frozen plasma
transfusion (Higgins 3)
3 Mean Difference (Fixed, 95% CI) 0.47 [-0.37, 1.30]
12 Variables of coagulation
- activated partial
thromboplastin time (s)
2 181 Mean Difference (IV, Fixed, 95% CI) 0.88 [-1.82, 3.58]
13 Variables of coagulation - other 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 Factor VIII (IU/L) 2 181 Mean Difference (IV, Fixed, 95% CI) -29.54 [-46.16, -12.
91]
13.2 von Willebrand factor
(IU/L)
2 181 Mean Difference (IV, Fixed, 95% CI) -31.39 [-47.71, -15.
06]
14 Plasma pH 12 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Postoperative pH 12 720 Mean Difference (IV, Random, 95% CI) 0.05 [0.04, 0.07]
14.2 Postoperative day 1 pH 2 91 Mean Difference (IV, Random, 95% CI) 0.01 [-0.00, 0.03]
15 Base excess (mmol/L) 9 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 Postoperative base excess 9 459 Mean Difference (IV, Random, 95% CI) 3.51 [2.61, 4.41]
15.2 Postoperative day 1 base
excess
3 138 Mean Difference (IV, Random, 95% CI) 2.48 [1.61, 3.36]
16 Serum bicarbonate (mmol/L) 8 478 Mean Difference (IV, Random, 95% CI) 3.14 [2.30, 3.98]
17 Serum glucose (mmol/L) 3 145 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.29, 0.29]
18 Serum chloride (mmol/L) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 Postoperative chloride 10 530 Mean Difference (IV, Random, 95% CI) -6.77 [-10.17, -3.38]
18.2 Postoperative day 1
chloride
5 258 Mean Difference (IV, Random, 95% CI) -8.48 [-15.88, -1.08]
19 Serum potassium (mmol/L) 7 459 Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.14, 0.06]
20 Serum sodium (mmol/L) 8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
20.1 Postoperative sodium 8 474 Mean Difference (IV, Fixed, 95% CI) -2.26 [-2.84, -1.68]
20.2 Postoperative day 1
sodium
2 91 Mean Difference (IV, Fixed, 95% CI) -1.22 [-2.55, 0.12]
21 Serum lactate (mmol/L) 4 224 Mean Difference (IV, Random, 95% CI) 0.52 [-0.04, 1.08]
22 Postoperative length of hospital
stay (days)
5 348 Mean Difference (IV, Fixed, 95% CI) 0.37 [-0.72, 1.47]
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Analysis 1.1. Comparison 1 Buffered versus non-buffered, Outcome 1 Mortality (all time frames reported).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 1 Mortality (all time frames reported)
Study or subgroup Buffered Non-Buffered
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Base 2011 2/43 1/38 49.5 % 1.75 [ 0.18, 17.39 ]
Gan 1999 1/60 0/60 17.0 % 7.39 [ 0.15, 372.38 ]
Waters 2001 1/33 1/33 33.5 % 1.00 [ 0.06, 16.34 ]
Total (95% CI) 136 131 100.0 % 1.85 [ 0.37, 9.33 ]
Total events: 4 (Buffered), 2 (Non-Buffered)
Heterogeneity: Chi2 = 0.67, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Buffered versus non-buffered, Outcome 2 Organ system failure - renal
insufficiency requiring support.
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 2 Organ system failure - renal insufficiency requiring support
Study or subgroup Buffered Non-Buffered Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hadimioglu 2008 3/60 3/30 34.6 % 0.47 [ 0.09, 2.50 ]
O’Malley 2005 1/25 2/26 17.1 % 0.50 [ 0.04, 5.89 ]
Waters 2001 4/33 5/33 40.0 % 0.77 [ 0.19, 3.18 ]
Kim 2013 3/30 1/30 8.2 % 3.22 [ 0.32, 32.89 ]
Total (95% CI) 148 119 100.0 % 0.82 [ 0.34, 1.98 ]
Total events: 11 (Buffered), 11 (Non-Buffered)
Heterogeneity: Chi2 = 1.91, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Buffered versus non-buffered, Outcome 3 Urine output (mL).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 3 Urine output (mL)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Intraoperative urine output (mL)
Gan 1999 60 400 (254) 60 531 (585) 20.6 % -131.00 [ -292.37, 30.37 ]
Kim 2013 30 714 (432) 30 806 (539) 14.7 % -92.00 [ -339.18, 155.18 ]
Kulla 2008 29 745 (579) 32 612 (460) 13.8 % 133.00 [ -131.21, 397.21 ]
O’Malley 2005 25 2100 (1500) 26 1600 (1600) 2.3 % 500.00 [ -350.86, 1350.86 ]
Scheingraber 1999 12 1075 (799) 12 717 (459) 5.4 % 358.00 [ -163.35, 879.35 ]
Takil 2002 15 506 (111) 15 623 (607) 11.4 % -117.00 [ -429.27, 195.27 ]
Waters 2001 33 1098 (618) 33 1319 (748) 10.6 % -221.00 [ -552.04, 110.04 ]
Wilkes 2001 23 343 (349) 24 183 (135) 21.3 % 160.00 [ 7.49, 312.51 ]
Subtotal (95% CI) 227 232 100.0 % 6.10 [ -128.41, 140.61 ]
Heterogeneity: Tau2 = 16080.54; Chi2 = 13.62, df = 7 (P = 0.06); I2 =49%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Intraoperative urine output (mL) - sensitivity analysis after exclusion of O’Malley 2005
Gan 1999 60 400 (254) 60 531 (585) 24.0 % -131.00 [ -292.37, 30.37 ]
Kulla 2008 29 745 (579) 32 612 (460) 16.8 % 133.00 [ -131.21, 397.21 ]
Scheingraber 1999 12 1075 (799) 12 717 (459) 7.1 % 358.00 [ -163.35, 879.35 ]
Takil 2002 15 506 (111) 15 623 (607) 14.2 % -117.00 [ -429.27, 195.27 ]
Waters 2001 33 1098 (618) 33 1319 (748) 13.2 % -221.00 [ -552.04, 110.04 ]
Wilkes 2001 23 343 (349) 24 183 (135) 24.7 % 160.00 [ 7.49, 312.51 ]
Subtotal (95% CI) 172 176 100.0 % 9.93 [ -147.01, 166.87 ]
Heterogeneity: Tau2 = 19915.03; Chi2 = 11.68, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 0.12 (P = 0.90)
3 Renal transplant patients
Kim 2013 30 714 (432) 30 806 (539) 74.6 % -92.00 [ -339.18, 155.18 ]
O’Malley 2005 25 2100 (1500) 26 1600 (1600) 25.4 % 500.00 [ -350.86, 1350.86 ]
Subtotal (95% CI) 55 56 100.0 % 58.26 [ -446.70, 563.21 ]
Heterogeneity: Tau2 = 73048.81; Chi2 = 1.71, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.23 (P = 0.82)
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Analysis 1.4. Comparison 1 Buffered versus non-buffered, Outcome 4 Creatinine change (µmol/L).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 4 Creatinine change ( mol/L)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postoperative creatinine change ( mol/L)
Waters 2001 33 -13 (15.4) 33 -16 (14.7) 52.3 % 3.00 [ -4.26, 10.26 ]
Wilkes 2001 23 -8.2 (20) 24 9.7 (20) 47.7 % -17.90 [ -29.34, -6.46 ]
Subtotal (95% CI) 56 57 100.0 % -6.96 [ -27.42, 13.50 ]
Heterogeneity: Tau2 = 194.51; Chi2 = 9.14, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.67 (P = 0.50)
2 Postoperative day 1 creatinine change ( mol/L)
Waters 2001 33 4.29 (26.4) 33 -4.82 (25.11) 63.7 % 9.11 [ -3.32, 21.54 ]
Wilkes 2001 23 6.9 (30) 24 9.3 (30) 36.3 % -2.40 [ -19.56, 14.76 ]
Subtotal (95% CI) 56 57 100.0 % 4.94 [ -5.91, 15.78 ]
Heterogeneity: Tau2 = 7.81; Chi2 = 1.13, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.89 (P = 0.37)
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Analysis 1.5. Comparison 1 Buffered versus non-buffered, Outcome 5 Postoperative creatinine (µmol/L).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 5 Postoperative creatinine ( mol/L)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postoperative creatinine
Kulla 2008 29 73 (22) 32 79 (25) 45.9 % -6.00 [ -17.80, 5.80 ]
Nuraei 2010 54 530 (168) 54 460 (124) 2.1 % 70.00 [ 14.31, 125.69 ]
Waters 2001 33 80 (18) 33 80 (27) 52.1 % 0.0 [ -11.07, 11.07 ]
Subtotal (95% CI) 116 119 100.0 % -1.31 [ -9.30, 6.68 ]
Heterogeneity: Chi2 = 6.96, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 0.32 (P = 0.75)
2 Postoperative day 1 creatinine
Hadimioglu 2008 60 331 (171) 30 389 (274) 1.9 % -58.00 [ -165.17, 49.17 ]
Kim 2013 30 345 (239) 30 318 (141) 2.3 % 27.00 [ -72.30, 126.30 ]
Kulla 2008 29 80 (24) 32 86 (36) 95.8 % -6.00 [ -21.23, 9.23 ]
Subtotal (95% CI) 119 92 100.0 % -6.26 [ -21.17, 8.64 ]
Heterogeneity: Chi2 = 1.33, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
3 Postoperative day 3 creatinine
Hadimioglu 2008 60 186 (194) 30 168 (150) 16.6 % 18.00 [ -54.74, 90.74 ]
Khajavi 2008 26 194 (194) 26 168 (62) 14.4 % 26.00 [ -52.29, 104.29 ]
Nuraei 2010 54 141 (80) 54 150 (124) 56.8 % -9.00 [ -48.36, 30.36 ]
O’Malley 2005 25 186 (150) 26 203 (159) 12.2 % -17.00 [ -101.81, 67.81 ]
Subtotal (95% CI) 165 136 100.0 % -0.47 [ -30.12, 29.19 ]
Heterogeneity: Chi2 = 1.01, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
4 Postoperative week 1 creatinine
Hadimioglu 2008 60 128.5 (59) 30 133 (88) 32.7 % -4.50 [ -39.35, 30.35 ]
Kim 2013 30 141 (150) 30 115 (62) 11.8 % 26.00 [ -32.08, 84.08 ]
Nuraei 2010 54 124 (78) 54 133 (80) 44.7 % -9.00 [ -38.80, 20.80 ]
O’Malley 2005 25 141 (114) 26 168 (106) 10.9 % -27.00 [ -87.47, 33.47 ]
Subtotal (95% CI) 169 140 100.0 % -5.36 [ -25.29, 14.56 ]
Heterogeneity: Chi2 = 1.67, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.60)
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Analysis 1.6. Comparison 1 Buffered versus non-buffered, Outcome 6 Postoperative creatinine clearance
(mL/min).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 6 Postoperative creatinine clearance (mL/min)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Base 2011 43 109.7 (66.2) 38 94.3 (42.7) 38.7 % 15.40 [ -8.60, 39.40 ]
Hadimioglu 2008 60 163.5 (136.5) 30 186 (194) 3.7 % -22.50 [ -100.04, 55.04 ]
O’Malley 2005 25 94 (30) 26 81 (41) 57.6 % 13.00 [ -6.66, 32.66 ]
Total (95% CI) 128 94 100.0 % 12.61 [ -2.31, 27.54 ]
Heterogeneity: Chi2 = 0.84, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.098)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Buffered versus non-buffered, Outcome 7 PaCO2 (mmHg).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 7 PaCO2 (mmHg)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postoperative PaCO2
Hadimioglu 2008 60 29.25 (5.4) 30 29 (4) 20.6 % 0.25 [ -1.73, 2.23 ]
Kim 2013 30 35 (5) 30 34 (4) 15.4 % 1.00 [ -1.29, 3.29 ]
Kulla 2008 29 40 (8) 32 38 (5) 7.0 % 2.00 [ -1.39, 5.39 ]
Nuraei 2010 54 34.8 (6.5) 54 34.7 (6.5) 13.4 % 0.10 [ -2.35, 2.55 ]
Song 2015 25 36 (7.5) 25 34 (8) 4.4 % 2.00 [ -2.30, 6.30 ]
Takil 2002 15 42 (1) 15 40 (3) 31.5 % 2.00 [ 0.40, 3.60 ]
Wilkes 2001 23 37.6 (5.3) 24 38 (6) 7.7 % -0.40 [ -3.63, 2.83 ]
Subtotal (95% CI) 236 210 100.0 % 1.05 [ 0.15, 1.94 ]
Heterogeneity: Chi2 = 3.82, df = 6 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
2 Postoperative day 1 PaCO2
Kulla 2008 29 41 (4) 32 37 (5) 33.3 % 4.00 [ 1.74, 6.26 ]
Takil 2002 15 41 (1) 15 38 (3) 66.7 % 3.00 [ 1.40, 4.60 ]
Subtotal (95% CI) 44 47 100.0 % 3.33 [ 2.03, 4.64 ]
Heterogeneity: Chi2 = 0.50, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 5.00 (P < 0.00001)
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Analysis 1.8. Comparison 1 Buffered versus non-buffered, Outcome 8 Postoperative nausea and vomiting.
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 8 Postoperative nausea and vomiting
Study or subgroup Buffered Non-Buffered Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Moretti 2003 7/30 8/30 29.6 % 0.84 [ 0.26, 2.70 ]
Wilkes 2001 3/24 8/24 33.8 % 0.29 [ 0.07, 1.25 ]
Heidari 2011 11/30 12/30 36.7 % 0.87 [ 0.31, 2.46 ]
Total (95% CI) 84 84 100.0 % 0.66 [ 0.34, 1.30 ]
Total events: 21 (Buffered), 28 (Non-Buffered)
Heterogeneity: Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Buffered versus non-buffered, Outcome 9 Intraoperative blood loss (mL).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 9 Intraoperative blood loss (mL)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Intraoperative blood loss < 1000 mL
Khajavi 2008 26 488 (177) 26 457 (135) 35.6 % 31.00 [ -54.57, 116.57 ]
Kulla 2008 29 665 (569) 32 677 (475) 3.7 % -12.00 [ -276.52, 252.52 ]
O’Malley 2005 26 310 (190) 25 309 (162) 27.9 % 1.00 [ -95.78, 97.78 ]
Scheingraber 1999 12 704 (447) 12 962 (332) 2.6 % -258.00 [ -573.04, 57.04 ]
Walsh 1983 7 316 (105) 7 310 (69) 30.1 % 6.00 [ -87.08, 99.08 ]
Subtotal (95% CI) 100 102 100.0 % 5.90 [ -45.18, 56.99 ]
Heterogeneity: Chi2 = 3.05, df = 4 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Intraoperative blood loss≥ 1000 mL
Gan 1999 60 1024 (949) 60 1278 (1616) 31.4 % -254.00 [ -728.19, 220.19 ]
Martin 2002 30 706 (646) 30 1012 (1477) 21.2 % -306.00 [ -882.87, 270.87 ]
Song 2015 25 2129 (1250) 25 1848 (1000) 17.9 % 281.00 [ -346.49, 908.49 ]
Takil 2002 15 1856 (637) 15 2356 (1072) 17.7 % -500.00 [ -1131.05, 131.05 ]
Waters 2001 33 2995 (2296) 33 3835 (3790) 3.1 % -840.00 [ -2351.87, 671.87 ]
Wilkes 2001 24 1765 (1797) 24 1348 (1378) 8.6 % 417.00 [ -488.98, 1322.98 ]
Subtotal (95% CI) 187 187 100.0 % -173.07 [ -438.83, 92.68 ]
Heterogeneity: Chi2 = 5.74, df = 5 (P = 0.33); I2 =13%
Test for overall effect: Z = 1.28 (P = 0.20)
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Analysis 1.10. Comparison 1 Buffered versus non-buffered, Outcome 10 Intraoperative red cell transfusion.
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 10 Intraoperative red cell transfusion
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
O’Malley 2005 25 310 (190) 26 309 (162) 82.0 % 1.00 [ -96.08, 98.08 ]
Scheingraber 1999 12 704 (447) 12 962 (332) 7.8 % -258.00 [ -573.04, 57.04 ]
Takil 2002 15 960 (680) 15 1280 (560) 3.9 % -320.00 [ -765.79, 125.79 ]
Wilkes 2001 23 481 (612) 24 439 (616) 6.3 % 42.00 [ -309.13, 393.13 ]
Total (95% CI) 75 77 100.0 % -29.10 [ -117.03, 58.84 ]
Heterogeneity: Chi2 = 4.19, df = 3 (P = 0.24); I2 =28%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Buffered versus non-buffered, Outcome 11 Intraoperative transfusion - other
products (log values).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 11 Intraoperative transfusion - other products (log values)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
1 Platelet transfusion (Higgins 3)
Gan 1999 1.589744 (0.9322432) 30.8 % 1.59 [ -0.24, 3.42 ]
Martin 2002 0.7826087 (1.49917) 11.9 % 0.78 [ -2.16, 3.72 ]
Waters 2001 1.48 (0.7954416) 42.3 % 1.48 [ -0.08, 3.04 ]
Wilkes 2001 0.1538462 (1.337198) 15.0 % 0.15 [ -2.47, 2.77 ]
Subtotal (95% CI) 100.0 % 1.23 [ 0.22, 2.25 ]
Heterogeneity: Chi2 = 0.98, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
2 Fresh frozen plasma transfusion (Higgins 3)
Gan 1999 1.05 (0.7971989) 28.7 % 1.05 [ -0.51, 2.61 ]
Waters 2001 0.2474916 (0.5909793) 52.2 % 0.25 [ -0.91, 1.41 ]
Wilkes 2001 0.1851852 (0.9785222) 19.1 % 0.19 [ -1.73, 2.10 ]
Subtotal (95% CI) 100.0 % 0.47 [ -0.37, 1.30 ]
Heterogeneity: Chi2 = 0.76, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Chi2 = 1.30, df = 1 (P = 0.25), I2 =23%
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Analysis 1.12. Comparison 1 Buffered versus non-buffered, Outcome 12 Variables of coagulation - activated
partial thromboplastin time (s).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 12 Variables of coagulation - activated partial thromboplastin time (s)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gan 1999 60 43 (31) 60 44 (30) 6.1 % -1.00 [ -11.92, 9.92 ]
Kulla 2008 29 35 (6) 32 34 (5) 93.9 % 1.00 [ -1.79, 3.79 ]
Total (95% CI) 89 92 100.0 % 0.88 [ -1.82, 3.58 ]
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Buffered versus non-buffered, Outcome 13 Variables of coagulation - other.
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 13 Variables of coagulation - other
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Factor VIII (IU/L)
Gan 1999 60 120 (90) 60 140 (90) 26.6 % -20.00 [ -52.21, 12.21 ]
Kulla 2008 29 83 (33) 32 116 (44) 73.4 % -33.00 [ -52.41, -13.59 ]
Subtotal (95% CI) 89 92 100.0 % -29.54 [ -46.16, -12.91 ]
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 3.48 (P = 0.00050)
2 von Willebrand factor (IU/L)
Gan 1999 60 110 (60) 60 140 (100) 30.6 % -30.00 [ -59.51, -0.49 ]
Kulla 2008 29 126 (39) 32 158 (39) 69.4 % -32.00 [ -51.60, -12.40 ]
Subtotal (95% CI) 89 92 100.0 % -31.39 [ -47.71, -15.06 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 3.77 (P = 0.00016)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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Analysis 1.14. Comparison 1 Buffered versus non-buffered, Outcome 14 Plasma pH.
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 14 Plasma pH
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postoperative pH
Base 2011 43 7.38 (0.04) 38 7.36 (0.04) 12.2 % 0.02 [ 0.00, 0.04 ]
Hadimioglu 2008 60 7.43 (0.06) 30 7.36 (0.05) 10.6 % 0.07 [ 0.05, 0.09 ]
Khajavi 2008 26 7.34 (0.05) 26 7.29 (0.08) 7.6 % 0.05 [ 0.01, 0.09 ]
Kim 2013 30 7.41 (0.05) 30 7.35 (0.04) 10.8 % 0.06 [ 0.04, 0.08 ]
Kulla 2008 29 7.38 (0.06) 32 7.35 (0.07) 8.4 % 0.03 [ 0.00, 0.06 ]
Nuraei 2010 54 7.31 (0.06) 54 7.27 (0.07) 10.3 % 0.04 [ 0.02, 0.06 ]
O’Malley 2005 25 7.37 (0.07) 26 7.28 (0.07) 7.1 % 0.09 [ 0.05, 0.13 ]
Scheingraber 1999 12 7.4 (0.12) 12 7.28 (0.12) 1.9 % 0.12 [ 0.02, 0.22 ]
Song 2015 25 7.41 (0.06) 25 7.37 (0.07) 7.6 % 0.04 [ 0.00, 0.08 ]
Takil 2002 15 7.34 (0.02) 15 7.26 (0.06) 8.5 % 0.08 [ 0.05, 0.11 ]
Waters 2001 33 7.4 (0.07) 33 7.35 (0.09) 7.1 % 0.05 [ 0.01, 0.09 ]
Wilkes 2001 23 7.42 (0.05) 24 7.35 (0.07) 7.9 % 0.07 [ 0.04, 0.10 ]
Subtotal (95% CI) 375 345 100.0 % 0.05 [ 0.04, 0.07 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 28.09, df = 11 (P = 0.003); I2 =61%
Test for overall effect: Z = 7.50 (P < 0.00001)
2 Postoperative day 1 pH
Kulla 2008 29 7.39 (0.05) 32 7.37 (0.04) 46.8 % 0.02 [ 0.00, 0.04 ]
Takil 2002 15 7.36 (0.03) 15 7.35 (0.03) 53.2 % 0.01 [ -0.01, 0.03 ]
Subtotal (95% CI) 44 47 100.0 % 0.01 [ 0.00, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
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Analysis 1.15. Comparison 1 Buffered versus non-buffered, Outcome 15 Base excess (mmol/L).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 15 Base excess (mmol/L)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postoperative base excess
Hadimioglu 2008 60 -0.77 (1.57) 30 -4.29 (2.12) 14.6 % 3.52 [ 2.66, 4.38 ]
Kim 2013 30 -2.3 (3.3) 30 -6 (4.2) 9.6 % 3.70 [ 1.79, 5.61 ]
Kulla 2008 29 -1.8 (2.5) 32 -4.2 (3.1) 11.9 % 2.40 [ 0.99, 3.81 ]
McFarlane 1994 15 -1.2 (1.1) 15 -5 (2.1) 13.0 % 3.80 [ 2.60, 5.00 ]
Scheingraber 1999 12 -0.8 (2) 12 -6.7 (2) 11.0 % 5.90 [ 4.30, 7.50 ]
Song 2015 25 -1.9 (2) 25 -5.8 (4.9) 8.9 % 3.90 [ 1.83, 5.97 ]
Takil 2002 15 -2.5 (2.7) 15 -8.3 (3.4) 8.4 % 5.80 [ 3.60, 8.00 ]
Waters 2001 33 -2.2 (2) 33 -3.8 (3.9) 11.5 % 1.60 [ 0.10, 3.10 ]
Wilkes 2001 24 -2 (2.6) 24 -3.8 (2.9) 11.2 % 1.80 [ 0.24, 3.36 ]
Subtotal (95% CI) 243 216 100.0 % 3.51 [ 2.61, 4.41 ]
Heterogeneity: Tau2 = 1.26; Chi2 = 26.32, df = 8 (P = 0.00093); I2 =70%
Test for overall effect: Z = 7.65 (P < 0.00001)
2 Postoperative day 1 base excess
Kulla 2008 29 -0.4 (2.5) 32 -3.4 (3) 40.2 % 3.00 [ 1.62, 4.38 ]
Takil 2002 15 -1 (1.6) 15 -3.5 (2.8) 28.8 % 2.50 [ 0.87, 4.13 ]
Wilkes 2001 23 -2 (2.6) 24 -3.8 (2.9) 31.0 % 1.80 [ 0.23, 3.37 ]
Subtotal (95% CI) 67 71 100.0 % 2.48 [ 1.61, 3.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 5.56 (P < 0.00001)
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Analysis 1.16. Comparison 1 Buffered versus non-buffered, Outcome 16 Serum bicarbonate (mmol/L).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 16 Serum bicarbonate (mmol/L)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hadimioglu 2008 60 22.01 (3.65) 30 18.2 (2.9) 13.6 % 3.81 [ 2.42, 5.20 ]
Kim 2013 30 22.5 (2.6) 30 19 (3.5) 12.4 % 3.50 [ 1.94, 5.06 ]
Nuraei 2010 54 19 (4.4) 54 16.4 (4.1) 12.1 % 2.60 [ 1.00, 4.20 ]
O’Malley 2005 25 21 (4) 26 18 (3) 10.0 % 3.00 [ 1.05, 4.95 ]
Scheingraber 1999 12 23 (1.1) 11 18.4 (2) 14.0 % 4.60 [ 3.26, 5.94 ]
Song 2015 25 23 (4) 25 21 (4) 8.6 % 2.00 [ -0.22, 4.22 ]
Takil 2002 15 22.7 (1.7) 15 18.8 (2) 14.0 % 3.90 [ 2.57, 5.23 ]
Waters 2001 33 22.5 (2) 33 21.1 (2.7) 15.4 % 1.40 [ 0.25, 2.55 ]
Total (95% CI) 254 224 100.0 % 3.14 [ 2.30, 3.98 ]
Heterogeneity: Tau2 = 0.85; Chi2 = 17.26, df = 7 (P = 0.02); I2 =59%
Test for overall effect: Z = 7.34 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Buffered versus non-buffered, Outcome 17 Serum glucose (mmol/L).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 17 Serum glucose (mmol/L)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Chin 2006 16 5.8 (0.5) 16 5.8 (0.4) 85.5 % 0.0 [ -0.31, 0.31 ]
Waters 2001 33 8.32 (2.6) 33 8.82 (2.46) 5.6 % -0.50 [ -1.72, 0.72 ]
Wilkes 2001 23 6.7 (1.5) 24 6.4 (1.9) 8.8 % 0.30 [ -0.68, 1.28 ]
Total (95% CI) 72 73 100.0 % 0.00 [ -0.29, 0.29 ]
Heterogeneity: Chi2 = 1.01, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Buffered versus non-buffered, Outcome 18 Serum chloride (mmol/L).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 18 Serum chloride (mmol/L)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postoperative chloride
Base 2011 43 110 (3.8) 38 111.8 (3.76) 10.1 % -1.80 [ -3.45, -0.15 ]
Hadimioglu 2008 60 104.75 (2.33) 30 121.4 (2.9) 10.3 % -16.65 [ -17.84, -15.46 ]
Kulla 2008 29 110 (3) 32 114 (5) 10.0 % -4.00 [ -6.05, -1.95 ]
McFarlane 1994 15 100.6 (1.2) 15 106.9 (2.3) 10.2 % -6.30 [ -7.61, -4.99 ]
O’Malley 2005 25 106 (4) 26 111 (4) 10.0 % -5.00 [ -7.20, -2.80 ]
Scheingraber 1999 12 102 (2) 12 111 (2.5) 10.1 % -9.00 [ -10.81, -7.19 ]
Song 2015 25 111 (5) 25 115 (3) 9.9 % -4.00 [ -6.29, -1.71 ]
Takil 2002 15 114 (4) 15 122 (4) 9.7 % -8.00 [ -10.86, -5.14 ]
Waters 2001 33 107 (4) 33 114 (6) 9.9 % -7.00 [ -9.46, -4.54 ]
Wilkes 2001 23 108.2 (3.4) 24 114 (4.9) 9.9 % -5.80 [ -8.20, -3.40 ]
Subtotal (95% CI) 280 250 100.0 % -6.77 [ -10.17, -3.38 ]
Heterogeneity: Tau2 = 28.83; Chi2 = 301.08, df = 9 (P<0.00001); I2 =97%
Test for overall effect: Z = 3.91 (P = 0.000091)
2 Postoperative day 1 chloride
Hadimioglu 2008 30 105 (3) 30 124.2 (2.9) 20.4 % -19.20 [ -20.69, -17.71 ]
Kim 2013 30 102 (4.3) 30 105 (4.2) 20.2 % -3.00 [ -5.15, -0.85 ]
Kulla 2008 29 110 (3) 32 114 (5) 20.2 % -4.00 [ -6.05, -1.95 ]
Takil 2002 15 109 (7) 15 115 (5) 19.2 % -6.00 [ -10.35, -1.65 ]
Wilkes 2001 23 104 (4) 24 114 (5) 20.0 % -10.00 [ -12.58, -7.42 ]
Subtotal (95% CI) 127 131 100.0 % -8.48 [ -15.88, -1.08 ]
Heterogeneity: Tau2 = 69.48; Chi2 = 219.48, df = 4 (P<0.00001); I2 =98%
Test for overall effect: Z = 2.24 (P = 0.025)
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Analysis 1.19. Comparison 1 Buffered versus non-buffered, Outcome 19 Serum potassium (mmol/L).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 19 Serum potassium (mmol/L)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hadimioglu 2008 60 3.8 (0.35) 30 3.9 (0.4) 35.5 % -0.10 [ -0.27, 0.07 ]
Khajavi 2008 26 4 (0.8) 26 4.8 (0.7) 6.0 % -0.80 [ -1.21, -0.39 ]
Kulla 2008 29 4.2 (0.3) 32 4.1 (0.5) 24.0 % 0.10 [ -0.10, 0.30 ]
Nuraei 2010 54 4.4 (0.87) 54 4.3 (0.62) 12.4 % 0.10 [ -0.18, 0.38 ]
O’Malley 2005 25 4.6 (0.6) 26 4.5 (0.8) 6.7 % 0.10 [ -0.29, 0.49 ]
Song 2015 25 3.9 (4) 25 3.9 (4) 0.2 % 0.0 [ -2.22, 2.22 ]
Wilkes 2001 23 4 (0.4) 24 4 (0.5) 15.1 % 0.0 [ -0.26, 0.26 ]
Total (95% CI) 242 217 100.0 % -0.04 [ -0.14, 0.06 ]
Heterogeneity: Chi2 = 17.10, df = 6 (P = 0.01); I2 =65%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Buffered versus non-buffered, Outcome 20 Serum sodium (mmol/L).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 20 Serum sodium (mmol/L)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postoperative sodium
Khajavi 2008 26 136 (4.5) 26 140 (3.2) 7.5 % -4.00 [ -6.12, -1.88 ]
Kim 2013 30 134 (4) 30 136 (3) 10.6 % -2.00 [ -3.79, -0.21 ]
Kulla 2008 29 140 (3) 32 142 (2) 20.3 % -2.00 [ -3.29, -0.71 ]
Nuraei 2010 54 136.4 (4.9) 54 136.1 (4.3) 11.2 % 0.30 [ -1.44, 2.04 ]
Song 2015 25 137 (2) 25 139 (3) 17.0 % -2.00 [ -3.41, -0.59 ]
Takil 2002 15 141 (3) 15 144 (2) 10.2 % -3.00 [ -4.82, -1.18 ]
Waters 2001 33 139 (3) 33 143 (4) 11.7 % -4.00 [ -5.71, -2.29 ]
Wilkes 2001 23 137.7 (2.7) 24 140 (3.3) 11.5 % -2.30 [ -4.02, -0.58 ]
Subtotal (95% CI) 235 239 100.0 % -2.26 [ -2.84, -1.68 ]
Heterogeneity: Chi2 = 15.91, df = 7 (P = 0.03); I2 =56%
Test for overall effect: Z = 7.61 (P < 0.00001)
2 Postoperative day 1 sodium
Kulla 2008 29 141 (3) 32 142 (3) 78.3 % -1.00 [ -2.51, 0.51 ]
Takil 2002 15 139 (4) 15 141 (4) 21.7 % -2.00 [ -4.86, 0.86 ]
Subtotal (95% CI) 44 47 100.0 % -1.22 [ -2.55, 0.12 ]
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.074)
-10 -5 0 5 10
Favours Buffered Favours Non-Buffered
74Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical
procedures (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.21. Comparison 1 Buffered versus non-buffered, Outcome 21 Serum lactate (mmol/L).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 21 Serum lactate (mmol/L)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kulla 2008 29 1.16 (0.73) 32 1.21 (0.65) 29.1 % -0.05 [ -0.40, 0.30 ]
Song 2015 25 1.4 (0.7) 25 1.2 (0.7) 28.3 % 0.20 [ -0.19, 0.59 ]
Waters 2001 33 4.1 (2.22) 33 2.8 (1.6) 17.1 % 1.30 [ 0.37, 2.23 ]
Wilkes 2001 23 2 (1.2) 24 1 (0.4) 25.6 % 1.00 [ 0.48, 1.52 ]
Total (95% CI) 110 114 100.0 % 0.52 [ -0.04, 1.08 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 15.60, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 1.83 (P = 0.067)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Buffered versus non-buffered, Outcome 22 Postoperative length of hospital
stay (days).
Review: Perioperative administration of buffered versus non-buffered crystalloid intravenous fluid to improve outcomes following adult surgical procedures
Comparison: 1 Buffered versus non-buffered
Outcome: 22 Postoperative length of hospital stay (days)
Study or subgroup Buffered Non-Buffered
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Base 2011 43 15.4 (20.25) 38 11.5 (21.75) 1.4 % 3.90 [ -5.29, 13.09 ]
Gan 1999 60 8.4 (7.7) 60 10.3 (7.8) 15.7 % -1.90 [ -4.67, 0.87 ]
O’Malley 2005 25 6.65 (3) 26 7.5 (7.4) 12.7 % -0.85 [ -3.93, 2.23 ]
Takil 2002 15 11 (2) 15 10 (2) 58.8 % 1.00 [ -0.43, 2.43 ]
Waters 2001 33 10.1 (8.3) 33 8.9 (4.7) 11.4 % 1.20 [ -2.05, 4.45 ]
Total (95% CI) 176 172 100.0 % 0.37 [ -0.72, 1.47 ]
Heterogeneity: Chi2 = 4.74, df = 4 (P = 0.32); I2 =16%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Table 1. Components of individual fluids (mmol/L when appropriate)
Normal
saline
Plasma-
lyte 148
(buffered)
Ringer’s
solution
(buffered)
Hextend
(buffered)
Hespan ’Crystal-
loid A’
(buffered)
HES 130/
0.42
(buffered)
Vitafusal
(buffered)
VitaHES
Sodium 154 140 130 143 154 140 140 130 154
Chloride 154 98 112 124 154 127 118 112.5 154
Potassium 0 0 5.4 3 0 4 4 5.5 0
Calcium 0 2.5 1.8 2.5 0 2.5 2.5 1 0
Magne-
sium
0 1.5 0 0.5 0 1 1 1 0
Lactate
(buffer)
0 23 27 (if lac-
tated)
28 0 0 0 0 0
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Table 1. Components of individual fluids (mmol/L when appropriate) (Continued)
Acetate
(buffer)
0 0 27 (if ac-
etated)
0 0 24 24 27 0
Maleate
(buffer)
0 0 0 0 0 5 5 0 0
Gluconate
(buffer)
0 23 0 0 0 0 0 0 0
Colloid 0 0 0 HES 670/
0.8
HES 450/
0.8
0 HES 130/
0.42
HES 130/
0.42
HES 130/
0.42
Dextrose
(g/L)
0 0 0 1 0 0 0 0 0
Manufacturers (when appropriate):
Plasmalyte 148: Baxter Healthcare Corporation, Deerfield, IL 60015, USA.
Ringer’s solution: non-proprietary.
Hextend: BioTime Inc., Berkeley, CA, USA.
Hespan: B Braun Medical Inc., Irvine, CA, USA.
Vitafusal: Serumwerk Bernburg AG, Bernberg, Germany.
VitaHES: Serumwerk Bernburg AG, Bernberg, Germany.
Table 2. Summary of trial interventions
Trial Buffered arm
intervention
Non-buffered
arm
intervention
Par-
ticipants given
buffered fluids
Participants
given non-
buffered fluids
Fluids given to
both arms
Notes
Base 2011 6% HES 130/0.
4 in balanced so-
lution (Volulyte)
6% HES 130/0.
4 in saline
(Voluven)
43 38 LactatedRinger’s Cardiac surgery
patients
Chin 2006 LactatedRinger’s Normal saline 16 16 None - com-
pletely buffered
vs completely
non-buffered
Minor
surgery, low fluid
volumes given
Gan 1999 Hextend and lac-
tated Ringer’s
Hespan and lac-
tated Ringer’s
60 60 LactatedRinger’s
(buffered)
Hadimioglu
2008
Lac-
tated Ringer’s or
Plasmalyte 148
Normal saline 60 30 None We
combined both
buffered fluid
arms for analysis
Heidari 2011 LactatedRinger’s Normal saline 30 30 None
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Table 2. Summary of trial interventions (Continued)
Khajavi 2008 LactatedRinger’s Normal saline 26 26 Blood as needed Admin-
istered during re-
nal transplanta-
tion surgery
Kim 2013 Plasmalyte 148 Normal saline 30 30 750 mL 5% al-
bumin
Admin-
istered during re-
nal transplanta-
tion surgery
Kulla 2008 130/0.
42 bufferedHES
and buffered
crystalloid
130/0.
42 non-buffered
HES and normal
saline
29 32 None Acetate buffer in
the buffered
group
Martin 2002 Hextend and lac-
tated Ringer’s
Hespan and lac-
tated Ringer’s
30 30 None Same participant
group
as in Moretti
2003 but differ-
ent outcomes de-
scribed
McFarlane 1994 Plasmalyte 148 Normal saline 15 15 None
Moretti 2003 Hextend and lac-
tated Ringer’s
Hespan and lac-
tated Ringer’s
30 30 LactatedRinger’s Same participant
group
as in Martin
2002 but differ-
ent outcomes de-
scribed
Nuraei 2010 LactatedRinger’s Normal saline 54 54 None Admin-
istered during re-
nal transplanta-
tion surgery
O’Malley 2005 LactatedRinger’s Normal saline 25 26 Nor-
mal saline with
20 mmol/L bi-
carbonate given
to each group
postoperatively
Scheingraber
1999
LactatedRinger’s Normal saline 12 12 None
Song 2015 Plasmalyte 148 Normal saline 25 25 6%
hydroxyethyl
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Table 2. Summary of trial interventions (Continued)
starch 130/0.4 in
0.9% saline ad-
ministered to re-
place blood loss
> 500 mL
Takil 2002 LactatedRinger’s Normal saline 15 15 500 mL gelofu-
sine given to each
participant
Walsh 1983 LactatedRinger’s Normal saline 7 7 None
Waters 2001 LactatedRinger’s Normal saline 33 33 Human albumin
given to both
arms
Wilkes 2001 Hextend and lac-
tated Ringer’s
Hespan and nor-
mal saline
23 24 None
Manufacturer:
Gelofusine: B Braun Melsungen AG, Melsungen, Germany/
HES: hydroxyethyl starch.
Table 3. Orphan outcomes
Study Outcome Participants Results
Base 2011 Respiratory failure 81 Four participants (9.3%) in buffered group and 1 (2.6%) in
non-buffered group developed respiratory failure
Gan 1999 Need for intraoperative calcium 120 Mean intraoperative calcium given was 4.2 mg in the
buffered group and 220 mg in the non-buffered group (P <
0.05)
Gan 1999 Prothrombin time 120 Prothrombin time for buffered group was 16 seconds (±
4) and for non-buffered group was 17 seconds (± 7). No
important differences between groups
Khajavi 2008 Renal artery thrombosis 52 2 participants in buffered fluids group (lactated Ringer’s)
developed renal artery thrombosis and subsequent graft fail-
ure.No similar incidences were recorded in the non-buffered
fluids group (normal saline). No important differences be-
tween groups
Kulla 2008 Blood loss on first postop day 61 Blood loss on first postoperative day in the buffered group
was 289 ± 325 mL and in the non-buffered group was 309
± 250 mL. No important differences between groups
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Table 3. Orphan outcomes (Continued)
Kulla 2008 Factor VIII at 6 hours postop and on
first postop day
61 Factor VIII levels at 6 hours postop was 141% ± 49 and
142% ± 49 for buffered and non-buffered groups, respec-
tively. No statistically significant differences
Factor VIII levels first postoperative day was 123% ± 47 and
132% ± 43 for buffered and non-buffered groups, respec-
tively. No important differences between groups
Kulla 2008 Ristocetin cofactor at 6 hours postop
and on first postop day
61 Ristocetin cofactor levels at 6 hours postop were 143% ±
15 and 148% ± 10 for buffered and non-buffered groups,
respectively. No statistically significant differences
Ristocetin cofactor levels on first postop day were 145% ±
14 and 150% ± 0 for buffered and non-buffered groups,
respectively. No important differences between groups
Moretti 2003 Postop nausea 60 Postoperative nausea was reported in 22 (73%) participants
in the buffered group and in 14 (47%) participants in the
non-buffered group
O’Malley 2005 Serum creatinine 6 months postop 51 Serum creatinine at 6 months was 133 ± 54 µmol/L and
133 ± 35 µmol/L for buffered and non-buffered groups,
respectively
Song 2015 Rotational Thromboelastography 50 ROTEM analyses revealed that values of MCF in FibTEM,
CFT, a angle and MCF in INTEM, CT, CFT, a angle and
MCF in EXTEM at end of surgery were changed towards
a hypocoagulable state compared with their corresponding
baseline values in both groups (P < 0.05). However, no im-
portant differences inFibTEM, INTEM, andEXTEManal-
yses were noted between Plasmalyte and NS groups
Takil 2002 Serum bicarbonate at 5 to 10 hours
postop
30 Serum bicarbonate at 6 hours was 23.6 ± 2.2 mmol/L and
19.3 ± 2.2 mmol/L for buffered and non-buffered groups,
respectively (P < 0.01)
Wilkes 2001 Gastric tonometry 47 Gastric tonometry showed P(g-a)CO2 of 0.9 ± 1.1 kPa in
the balanced group and 1.7 ± 0.5 kPa in the unbalanced
group (P = 0.04)
Wilkes 2001 Serum total calcium 47 Postoperative total serum calcium was 2.0 ± 0.2 mmol/L
for the balanced group and 1.6 ± 0.2 mmol/L for the non-
balanced group (P = 0.0001)
Data potentially of interest to this review but reported only in single studies and therefore not suitable for numerical analysis.
CFT: clot formation time; CT: clotting time; EXTEM, FibTEM, INTEM: Trade names for types of ROTEM assay; kPa: kilopascals;
MCF: maximum clot firmness; mL: millilitres; mmol/L: millimols per litre; NS: normal saline; P(g-a)CO2: partial pressure of gastric
minus arterial carbon dioxide; postop: postoperative; ROTEM: manufacturer’s name of device - Rotational Thromboelastometry; s:
seconds;:µmol/L: micromols/litre.
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A P P E N D I C E S
Appendix 1. Search strategy for CENTRAL, the Cochrane Library
#1 MeSH descriptor Colloids, this term only
#2 colloid*:ti,ab
#3 crystalloid*
#4 MeSH descriptor Plasma Substitutes, this term only
#5 (lactated or colloid* or hyperchlor?emi* or crystalloid* or ringer or hartmann or “Fluid Therapy” or buffered):ti,ab
#6 (fluid* near (intravenous or replacement or resuscitation or balanced or non-balanced)):ti,ab
#7 saline:ti
#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9 MeSH descriptor Surgery explode all trees
#10 (surgery or surgical):ab
#11 (#9 OR #10)
#12 (#8 AND #11)
Appendix 2. Search strategy for MEDLINE (OvidSP)
1. colloid*.ti,ab. or Colloids/
2. crystalloid*.mp.
3. lactated.ti,ab. or Plasma Substitutes/
4. (hyperchlor?emi* or crystalloid* or ringer or hartmann).ti,ab.
5. Fluid Therapy.ti,ab. or Fluid Therapy/
6. (intravenous adj3 fluid*).ti,ab.
7. (fluid adj3 replacement).mp.
8. (fluid and resuscitation).ti,ab.
9. buffered.mp. or exp Bicarbonates/
10. ((balanced or non-balanced) adj3 fluid*).mp.
11. saline.ti.
12. 7 or 5 or8 or 1 or 6 or 2 or 10 or 4 or 3 or 11 or 9
13. Surgery/ or (surgery or surgical*).ti,ab.
14. 13 and 12
15. ((randomised controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or
randomly.ab. or trial.ti.) and humans.sh.
16. 15 and 14
Appendix 3. Search strategy for Embase (OvidSP)
1. colloid*.ti,ab. or Colloids/
2. crystalloid*.mp.
3. actated.ti,ab. or Plasma Substitutes/
4. (hyperchlor?emi* or crystalloid* or ringer or hartmann).ti,ab.
5. Fluid Therapy.ti,ab. or Fluid Therapy/
6. (intravenous adj3 fluid*).ti,ab.
7. (fluid adj3 replacement).mp.
8. (fluid and resuscitation).ti,ab.
9. buffered.mp. or exp Bicarbonates/
10. ((balanced or non-balanced) adj3 fluid*).mp.
11. saline.ti.
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
13. Surgery/ or (surgery or surgical*).ti,ab.
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14. 13 and 12
15. (placebo.sh. or controlled study.ab. or random*.ti,ab. or trial*.ti,ab.) and human*.ec,hw,fs.
16. 15 and 14
Appendix 4. Search strategy for CINAHL (EBSCOhost)
#1. TX (Fluid Therapy)
#2. (resuscitation or replacement or intravenous or balanced or non balanced) and fluid
#3. TX buffered or colloid* or crystalloid* or acetated or hyperchloremi* or hyperchloraemi* or crystalloid* or ringer or hartmann
#4. TI saline
#5. MW Bicarbonates or Fluid Therapy or Plasma Substitutes or Colloids
#6. #1 or #2 or #3 or #4 or #5
#7. TX surgery or surgical
#8. #6 and #7
#9. (MH “Clinical Trials+”)
#10. (“randomised”) or (MM “Random Assignment”)
#11. #9 or #10
#12. #8 and #11
Appendix 5. Search strategy in 2003
In 2003, the following search strategy, or variations of this strategy were performed:
#1 colloid.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#2 crystalloid.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#3 ringer$.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#4 hartmann$.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#5 lactated.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#6 hyperchloremic.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#7 hyperchloremia.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#8 hyperchloraemic.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#9 hyperchloraemia.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#10 fluidtherapy.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#11 fluid-therapy.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#12 (intravenous and fluid).mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#13 (intravascular and fluid).mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#14 (fluid adj2 therapy).mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#15 (fluid and replacement).mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#16 (fluid and resuscitation).mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#17 saline.mp. [mp=ti, ab, rw, sh, tn, ot, dm, mf, dv]
#18 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17
#19 RANDOMIZED CONTROLLED TRIAL.pt.
#20 CONTROLLED CLINICAL TRIAL.pt.
#21 RANDOMIZED CONTROLLED TRIALS.sh.
#22 RANDOM ALLOCATION.sh.
#23 DOUBLE BLIND METHOD.sh.
#24 SINGLE-BLIND METHOD.sh.
#25 or/19-24
26 (ANIMAL not HUMAN).sh.
#27 #25 not #26
#28 CLINICAL TRIAL.pt.
#29 exp CLINICAL TRIALS/MINOR
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#30 (clin$ adj25 trial$).ti,ab.
#31 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
#32 PLACEBOS.sh.
#33 placebo$.ti,ab.
#34 random$.ti,ab.
#35 RESEARCH DESIGN.sh.
#36 or/28-35
#37 #36 not #26
#38 #37 not #27
#39 COMPARATIVE STUDY.sh.
#40 exp EVALUATION STUDIES/
#41 FOLLOW UP STUDIES.sh.
#42 PROSPECTIVE STUDIES.sh.
#43 (control$ or prospectiv$ or volunteer$).ti,ab.
#44 or/39-43
#45 #44 not #26
#46 #45 not (#27 or #38)
#47 #27 or #38 or #46
#48 ((CHILD or PAEDIATRIC or PEDIATRIC or INFANT) not ADULT).sh.
#49 #47 not #48
#50 #18 and #49
WH A T ’ S N E W
Last assessed as up-to-date: 3 June 2016.
Date Event Description
3 June 2016 New search has been performed We performed a new search in June 2016 and identified 6
newpublications.We reviewed2 trials that previouslywere
awaiting classification, and included 1 (Nuraei 2010) and
excluded 1 (Choi 2010). In total, we extracted data from 5
new trials included in this updated review (Heidari 2011;
Khajavi 2008; Kim 2013; Nuraei 2010; Song 2015). We
excluded 3 trials (Choi 2010; Krebbel 2014; Young 2015)
. No further trials are awaiting classification. To ensure
that this updated review compliedwithMECIRReporting
Standards, we re-extracted and analysed data from all 19
primary publications
In this review, we updated the following sections: Ab-
stract, Plain language summary, Summary of main find-
ings, Methods, Results, PRISMA flow chart, Discussion,
References, Characteristics of studies, Data and analysis
(1.2, 1.3, 1.4, 1.5, 1.7, 1.8, 1.9, 1.14, 1.15, 1.16, 1.18, 1.
20, 1.21), and Additional tables
3 June 2016 New citation required but conclusions have not changed Conclusions of this updated reviewhave not been changed
by the inclusion of new studies. We have added 2 new
review authors (Bampoe S and Odor P) to the team. We
have updated the methods used to comply with current
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(Continued)
MECIR Reporting Standards and have updated quality
assessments to incorporate the GRADE method
H I S T O R Y
Protocol first published: Issue 1, 2003
Review first published: Issue 12, 2012
Date Event Description
11 February 2013 Amended We updated contact details.
4 January 2008 Amended We converted this review to new review format.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
When appropriate, we performed subgroup analysis for patients undergoing renal transplant surgery. We did not perform any of the
other planned subgroup analyses owing to lack of sufficient data.
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Medical Subject Headings (MeSH)
∗Surgical Procedures, Operative; Buffers; Fluid Therapy [adverse effects; ∗methods; mortality]; Perioperative Care [methods]; Plasma
Substitutes [administration & dosage]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Humans
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